Electronic Supplementary Material (ESI) for ChemComm. This journal is © The Royal Society of Chemistry 2015

A Systematic Approach to Diverse, Lead-Like Scaffolds from α,α -Disubstituted Amino Acids

Daniel J. Foley, Richard G. Doveston, Ian Churcher, Adam Nelson* and Stephen P. Marsden*

Supplementary Information

Contents:

1.0	Exe	Exemplar scaffold decoration2				
2.0	Con	nputational Analysis	2			
	2.1	Virtual Library Enumeration	2			
3.0	Nov	elty Assessment	6			
	3.1	Search 1: Murcko fragments against a random 5% of the ZINC database (453698 compounds)	6			
	3.2	Search 2: Scaffolds against the ZINC database (9039756 compounds)	7			
4.0	Lea	d-likeness Assessment	13			
5.0	Sha	pe Analysis – Principal Moments of Inertia	25			
6.0	Sca	ffold Diversity Assessment	25			
7.0	Ехр	erimental	27			
	7.1	General experimental	27			
	7.2	General procedures	28			
	7.3	Experimental data	33			
	7.4	Synthesis of scaffold derivatives	54			
8.0	Ref	erences	59			
a n	NMP Spectra					

1.0 Exemplar scaffold decoration

To confirm the validity of the library analysis, we demonstrated experimentally that *N*-deprotection and decoration reactions were viable (Scheme S1, **S7**, **S8**, **S9** and **S10**).

CO₂Me
$$N_1$$
 N_3
 N_3
 N_4
 N_5
 $N_$

Scheme S1. Exemplar scaffold diversifications. Reagents and conditions: i) phenyl acetylene (2.0 eq.), Cu(OAc)₂ (20 mol%), sodium ascorbate (40 mol%), 'BuOH/H₂O 1:1, 89%; ii) NaOH (2.2 eq.), MeOH, 80%; iii) NaOMe, MeOH, 76%; iv) 4-F-C₆H₄-CH₂Br (2.0 eq), NaH (1.1 eq), DMF, 1 h, 52%.

2.0 Computational Analysis

2.1 Virtual Library Enumeration

The virtual library was enumerated and manipulated using Accelrys Pipeline Pilot version 8.5 (Pipeline Pilot v8.5.0.200, Accelrys® Software Inc., 2011). The enumeration process is illustrated in Figure S1 and was based upon the 22 scaffolds detailed in the manuscript. To enumerate the virtual library, any protecting groups were removed and the manipulations shown in Scheme S2 were performed followed by the decoration reactions shown in Scheme S3, using the 80 capping groups shown in Figure S2. The underivatised scaffolds were retained in the final virtual library.





Figure S1. Overview of the process for the enumeration of the virtual library.



Scheme S2. Functional group manipulations of scaffolds (Manipulation 1) and final compounds (Manipulation 2).

Azide Decoration

$$R-N_3$$
 \longrightarrow $R-N$ $N \subset N$ Click

Amine Decoration (R¹ = H, alkyl)

Carbamate Decoration

Acid/aldehyde Decoration (R1 = H, alkyl, aryl)

Urea Decoration

Amide Decoration

Scheme S3. Decoration reactions exploited in the enumeration of the virtual library.




Figure S2. 80 capping reagents exploited in the enumeration of the virtual library.

3.0 Novelty Assessment

3.1 Search 1: Murcko fragments against a random 5% of the ZINC database (453698 compounds)

Substructure search (Figure S3):

- 1. Murcko fragments were generated then:
- 2. Exo-cylic alkenes both removed and reduced to methyl groups
- 3. Cyclic alkenes retained and reduced




Figure S3. Murcko fragments used in the substructure search against a random 5% of the ZINC database.

4 substructure hits found (Table S1)


Entry	Murcko assembly	Original Smiles	ZINC identity	Corresponding scaffold
1	NH NH	c1ccc(cc1)[C@@]23CCCN2 C(=O)CNC3=O	ZINC04753275	10a
2	NH NH	c1ccc(cc1)[C@]23CCCN2C(=O)CNC3=O	ZINC04753277	10a
3	OH ON NH ON NH	C[C@]1(CC[NH+]2[C@]13C [C@H]4[C@](C2)(C[C@@]5 (C4(C)C)c6ccc7c(c6NC5=O) OC=CC(O7)(C)C)N(C3=O)C)O	ZINC14637262	10a/16a
4	HO OH Me OH	CC(=O)O[C@@H]1CN2C(= O)C=C[C@@H]((C@@]2((C @@H]1OC(=O)C)C)OC(=O) C	ZINC22067059	16a

Table \$1. Substructure hits when the Murcko fragments (Figure S3) were searched for in a random 5% of the ZINC database.

3.2 Search 2: Scaffolds against the ZINC database (9039756 compounds)

Substructure search (Figure S4):

- 1. Esters converted to 'any carbonyl'
- 2. Azides converted to 'any N'
- 3. Exo-cylic alkenes both removed and reduced to methyl groups
- 4. Cyclic alkenes retained and reduced
- 5. Allyl groups converted to 'any carbonyl' and "dehomologated alkyl-H"



 $\textbf{Figure S4.} \ \textbf{Scaffolds used in the substructure search against the ZINC database}.$

28 substructure hits found (Table S2)

Entry	Structure	SMILES	ZINC identity	Corresponding scaffold
1	N N N N N N N N N N N N	C[C@@H](C[C@@] 12CCCN1C(=O)[C@ @H]3CCCN3C2=O) OC(=O)N	ZINC35457219	10a
2	O N NH ₂	C[C@@H](C[C@]12 CCCN1C(=O)[C@@ H]3CCCN3C2=O)OC (=O)N	ZINC35457226	10a
3	O NH ₂	C[C@H](C[C@@]12 CCCN1C(=O)[C@@ H]3CCCN3C2=O)OC (=O)N	ZINC35457222	10a
4	ON NH2	C[C@H](C[C@]12C CCN1C(=O)[C@@H] 3CCCN3C2=O)OC(= O)N	ZINC35457229	10a
5	CI N N N N	Cc1ccc(cc1)N2C(=O) [C@H]3[C@@H](N4 CCNC(=O)[C@@]4([C@@H]3C2=O)CC(=O)OC)c5ccc(cc5)Cl	ZINC85408785	10a
6	CI HN N	Cc1ccc(cc1)N2C(=O) [C@H]3[C@H](N4C CNC(=O)[C@@]4([C @@H]3C2=O)CC(= O)OC)c5ccc(cc5)CI	ZINC85408790	10a

Entry	Structure	SMILES	ZINC identity	Corresponding scaffold
7	HN	Cc1ccc(cc1)N2C(=O) [C@H]3[C@@H](N4 CCNC(=O)[C@@]4([C@@H]3C2=O)CC(=O)OC)c5ccc(cc5)O C	ZINC85408758	10a
8	HN N	Cc1ccc(cc1)N2C(=O) [C@H]3[C@H](N4C CNC(=O)[C@@]4([C @@H]3C2=O)CC(= O)OC)c5ccc(cc5)OC	ZINC85408763	10a
9	O Z O D D D D D D D D D D D D D D D D D	Cc1ccc(cc1)[C@@H] 2[C@@H]3[C@@H](C(=O)N(C3=O)c4ccc (cc4)C)[C@@]5(N2C CNC5=O)CC(=O)OC	ZINC19960843	10a
10	HN N	Cc1ccc(cc1)[C@H]2[C@@H]3[C@@H](C (=O)N(C3=O)c4ccc(c c4)C)[C@@]5(N2CC NC5=O)CC(=O)OC	ZINC36092083	10a
11		CCOC(=O)[C@@]1(CCCCN1C(=O)OC(C)(C)C)Cc2cccc2	ZINC67794623	16d
12		CCOC(=O)[C@]1(C CCCN1C(=O)OC(C)(C)C)Cc2cccc2	ZINC67794624	16d

Entry	Structure	SMILES	ZINC identity	Corresponding scaffold
13	HON	CC1(C=Cc2c(ccc3c2 N(C(=O)[C@@]34C[C@@]56[C@@H](C 4(C)C)C[C@]7(CCC N7C5=O)C(=O)N6)O)O1)C	ZINC31169877	10a/16a
14	HO N N N N N N N N N N N N N N N N N N N	CC1(C=Cc2c(ccc3c2 N(C(=O)[C@@]34C[C@]56[C@@H](C4(C)C)C[C@@]7(CCC N7C5=O)C(=O)N6)O)O1)C	ZINC35456356	10a/16a
15	HO N HN N	CC1(C=Cc2c(ccc3c2 N(C(=O)[C@]34C[C @@]56[C@@H](C4(C)C)C[C@]7(CCCN7 C5=O)C(=O)N6)O)O 1)C	ZINC31169880	10a/16a
16	HO N N N N N N N N N N N N N N N N N N N	CC1(C=Cc2c(ccc3c2 N(C(=O)[C@]34C[C @]56[C@@H](C4(C) C)C[C@@]7(CCCN7 C5=O)C(=O)N6)O)O 1)C	ZINC35456361	10a/16a
17	NH OH OH	CC1(C=Cc2c(ccc3c2 N=C4[C@]3(C[C@]5 6[C@H](C4(C)C)C[C @@]7(CCCN7C5=O)C(=O)N6)O)O1)C	ZINC31162601	10a/16a
18		CC1(C=Cc2c(ccc3c2 N[C@@]4(C3=O)C[C@@]56[C@@H](C 4(C)C)C[C@]7(CCC N7C5=O)C(=O)N6)O 1)C	ZINC31169883	10a/16a
19	N H N N N N N N N N N N N N N N N N N N	CC1(C=Cc2c(ccc3c2 N[C@@]4(C3=O)C[C@]56[C@@H](C4(C)C)C[C@@]7(CCC N7C5=O)C(=O)N6)O 1)C	ZINC35271063	10a/16a
20	H N N N N N N N N N N N N N N N N N N N	CC1(C=Cc2c(ccc3c2 N[C@]4(C3=O)C[C @@]56[C@@H](C4(C)C)C[C@]7(CCCN7 C5=O)C(=O)N6)O1) C	ZINC31169886	10a/16a

Entry	Structure	SMILES	ZINC identity	Corresponding scaffold
21	N H N N N N N N N N N N N N N N N N N N	CC1(C=Cc2c(ccc3c2 N[C@]4(C3=O)C[C @]56[C@@H](C4(C) C)C[C@@]7(CCCN7 C5=O)C(=O)N6)O1) C	ZINC35271065	10a/16a
22	NH N	CC1(C=Cc2c(ccc3c2 [nH]c4c3C[C@@]56[C@@H](C4(C)C)C[C @]7(CCCN7C5=O)C (=O)N6)O1)C	ZINC14856966	10a/16a
23	ON NET OF THE PROPERTY OF THE	CC1(C=Cc2c(ccc3c2 [nH]c4c3C[C@]56[C @@H](C4(C)C)C[C @@]7(CCCN7C5=O)C(=O)N6)O1)C	ZINC13373546	10a/16a
24	TZ V	CC1(C=Cc2c(ccc3c2 [nH]c4c3C[C@]56[C @H](C4(C)C)C[C@ @]7(CCCN7C5=O)C (=O)N6)O1)C	ZINC13373547	10a/16a
25	HN NN N	C[C@@H]1CC[NH+] 2[C@@]13C[C@H]4[C@@](C2)(C[C@]5(C4(C)C)c6ccc7c(c6N C5=O)C(=O)CC(O7)(C)C)N(C3=O)C	ZINC72320575	10a/16a
26	HN N N N N N N N N N N N N N N N N N N	C[C@H]1CC[NH+]2[C@@]13C[C@H]4[C @@](C2)(C[C@]5(C 4(C)C)c6ccc7c(c6NC 5=O)C(=O)CC(O7)(C)C)N(C3=O)C	ZINC72320576	10a/16a
27	HN OH	C[C@]1(CC[NH+]2[C @]13C[C@@H]4[C @](C2)(C[C@@]5(C 4(C)C)c6ccc7c(c6NC 5=O)OC=CC(O7)(C) C)N(C3=O)C)O	ZINC14637263	10a/16a
28	HN N N OH	C[C@]1(CC[NH+]2[C @]13C[C@H]4[C@](C2)(C[C@@]5(C4(C) C)c6ccc7c(c6NC5=O)OC=CC(O7)(C)C)N(C3=O)C)O	ZINC14637262	10a/16a

Table S2. Substructure hits when the scaffolds (Figure S4) were searched for in the ZINC database.

4.0 Lead-likeness Assessment

AlogP and number of heavy atoms were calculated using the tools within Pipeline Pilot. The fraction of sp^3 -hybridised carbon atoms (F sp^3) was calculated using Dotmatics Vortex (Vortex v2013.12.25046). The data were visualized and analysed using Vortex.

The structural filtering was performed by interrogating two sets of SMARTS definitions with each of the final compounds using the substructure search tool within Pipeline Pilot. The first set contained 240 definitions (Table S3) as compiled by Shoichet, Simeonev *et al.* and used at the NIH Chemical Genomics Centre.¹ The second set contained 36 definitions (Table S4) and are examples from the 'GSKB' filter as described by Churcher *et al.*² In addition, the structural element of the high throughput screening filter embedded in Pipeline Pilot was also used, which comprises the filters for undesirable functionality outlined in Table S5.

Data from our lead-likeness assessment of both the ZINC database of compounds 'available now'³ and our virtual library are provided in Tables S6, S7 and S8. The distribution of the molecular properties of the virtual library is shown in Figure S6. The distribution for each scaffold is shown in Figure S7.

Filter	SMARTS
2,3,4-trihydroxyphenyl	c([OH])c([OH])
2,4,5-trihydroxyphenyl	c([OH])c([OH])cc([OH])
	[#7;R1]1[#6]([F,Cl,Br,l])[#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
2halo_pyrazine_3EWG]),\$(C=O)])[#7][#6][#6]1
	[#7;R1]1[#6]([F,Cl,Br,l])[#6;!\$(c-N)][#7][#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)(O-D)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$(N+](=O)(O-D))
2halo_pyrazine_5EWG]),\$(C=O)])[#6;!\$(c-N)]1
	[#7;R1]1[#6]([F,Cl,Br,l])[#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
2halo_pyridazine_3EWG]),\$(C=O)])[#6][#6][#7]1
	[#7;R1]1[#6]([F,Cl,Br,l])[#6][#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
2halo_pyridazine_5EWG]),\$(C=O)])[#7]1
	[#7;R1]1[#6;!\$(c=O)]([F,Cl,Br,I])[#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
2halo_pyridine_3EWG]),\$(C=O)])[#6;!\$(c-N)][#6][#6;!\$(c-N)]1
	[#7;R1]1[#6;!\$(c=O)]([F,Cl,Br,I])[#6][#6;!\$(c-
2halo_pyridine_5EWG	N)][#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-]),\$(C=O)])[#6;!\$(c=O);!\$(c-N)]1
	[#7;R1]1[#6]([F,CI,Br,I])[#7][#6][#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O+I])]
2halo_pyrimidine_5EWG]),\$(C=O)])[#6]1
2-Halopyridine	[F,Cl,Br]-c1n[c,n][c,n][c,n]1
	[#7;R1]1[#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
3halo_pyridazine_2EWG]),\$(C=O)])[#6]([F,Cl,Br,I])[#6][#7]1
	[#7;R1]1[#6][#6]([F,Cl,Br,I])[#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
3halo_pyridazine_4EWG]),\$(C=O)])[#6][#7]1

Filter	SMARTS
	[#7,#8,#16]1~[#6;H]~[#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
4_pyridone_3_5_EWG	$]), \\ \\ (C=O)]) \sim [\#6]([S(S=O)(=O)), \\ \\ (C(F)(F)(F)), \\ \\ (C\#N), \\ \\ (N(=O)(=O)), \\ \\ ([N+](=O)[O-]), \\ \\ (C=O)]) \sim [\#6; H] \\ \\ (C=O)[O-]), \\ \\ (C=O)[O-]), \\ (C=O)[O-]$
	[#7;R1]1[#6;!\$(c=O);!\$(c-N)][#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
4halo_pyridine_3EWG]),\$(C=O)])[#6]([F,CI,Br,I])[#6][#6;!\$(c=O);!\$(c-N)]1
	[#7]1[#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
	$]), \\ \\ (C=O)])[\#7; \\ R1][\#6]([F,CI,Br,I])[\#6][\#6]1([\\ \\ (S(=O)(=O)),\\ \\ \\ (C(F)(F)(F)),\\ \\ (C\#N),\\ \\ \\ (N(=O)(=O)),\\ \\ \\ ([N+](=O)[O-N])([N+](N+I))([N+I)(N+I)(N+I)(N+I)(N+I)(N+I)(N+I)(N+I)($
4halo_pyrimidine_2_6EWG]),\$(C=O)])
	[#7]1[#6][#7;R1][#6]([F,Cl,Br,I])[#6]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
4halo_pyrimidine_5EWG]),\$(C=O)])[#6]1
acetal	[#6]-O[CH1](-[#6])O[#6]
acid_halide	[S,C](=[O,S])[F,Br,Cl,I]
acrylate	[CH2]=[C;!\$(C-N);!\$(C-O)]C(=O)
activated_4mem_ring	[#6]1~[\$(C(=O)),\$(S(=O))]~[O,S,N]~[\$(C(=O)),\$(S(=O))]1
activated_acetylene	[\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-]),\$(C(=O))]C#[C;!\$(C-N);!\$(C-n)]
	[N;!R]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
activated_diazo	$]), \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$
activated_S#O_3_ring	C1~[O,S]~[C,N,O,S]1[a,N,O,S]
	O = COC = [\$(C(S(=O)(=O))), \$(C(C(F)(F)(F))), \$(C(C#N)), \$(C(N(=O)(=O))), \$(C([N+](=O)[O+N)), \$(C(N(=O)(=O))), \$(C(N(=O)(=O)(=O))), \$(C(N(=O)(=O)(=O))), \$(C(N(=O)(=O)(=O))), \$(C(N(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)
activated_vinyl_ester])),\$(C(C(=O)));!\$(C(N))]
	O(-S(=O)(=O))C = [\$(C(S(=O)(=O))), \$(C(C(F)(F)(F))), \$(C(C#N)), \$(C(N(=O)(=O))), \$(C([N+](=O)[O+N)), \$(C(N(=O)(=O))), \$(C(N(=O)(=O)(=O))), \$(C(N(=O)(=O)(=O))), \$(C(N(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)
activated_vinyl_sulfonate])),\$(C(C(=O)));!\$(C(N))]
acyclic_imide	[C,c][C;!R](=O)[N;!R][C;!R](=O)[C,c]
acyl_123_triazole	[#7;R1]1~[#7;R1]~[#7;R1](-C(=O))~[#6]~[#6]1
acyl_134_triazole	[#7]1~[#7]~[#6]~[#7](-C(=O)[!N])~[#6]1
acyl_activated_NO	O=C(-[!N])O[\$([#7;+]),\$(N(C=[O,S,N])(C=[O,S,N]))]
acyl_cyanide	C(=O)-C#N
acyl_imidazole	[C;!\$(C-N)](=O)[#7]1[#6;H1,\$([#6]([*;!R]))][#7][#6;H1,\$([#6]([*;!R]))][#6;H1,\$([#6]([*;!R]))]1
acyl_pyrazole	[C;!\$(C-N)](=O)[#7]1[#7][#6;H1,\$([#6]([*;!R]))][#6;H1,\$([#6]([*;!R]))][#6;H1,\$([#6]([*;!R]))]1
aldehyde	[C,c][C;H1](=O)
aliphatic_chain_6	[CD2;R0][CD2;R0][CD2;R0][CD2;R0][CD2;R0]
alkynyl_michael_acceptor1	[#6]-C#CC(=O)-[#6,#7,#8]
alkynyl_michael_acceptor2	[CH1]#CC(=O)-[#6,#7,#8]
allene	*=C=*
alpha_dicarbonyl	C(=O)! @C(=O)
alpha_halo_amine	[F,Cl,Br,I,\$(O(S(=O)(=O)))]-[CH,CH2;!\$(CF2)]-[N,n]
alpha_halo_carbonyl	C(=O)([CH,CH2][Cl,Br,l,\$(O(S(=O)(=O)))])
alpha_halo_EWG	[\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-])]-[CH,CH2]-[CI,Br,I,\$(O(S(=O)(=O)))]
alpha_halo_heteroatom	[N,n,O,S;!\$(S(=O)(=O))]-[CH,CH2;!\$(CF2)][F,CI,Br,I,\$(O(S(=O)(=O)))]
alpha_halo_heteroatom_tert	[N,n,O,S;!\$(S(=O)(=O))]-C([Cl,Br,l,\$(O(S(=O)(=O)))])(C)(C)
anhydride	[\$(C(=O)),\$(C(=S))]-[O,S]-[\$(C(=O)),\$(C(=S)),\$(C(=[N;!R])),\$(C(=N(-[C;X4])))]
aromatic_azide c	N=[N+]=[N-]
aryl_phosphonate	P(=O)-[O;!R]-a
aryl_thiocarbonyl	a-[S;X2;!R]-[C;!R](=O)
azide	[\$(N#[N+]-[N-]),\$([N-]=[N+]=N)]
aziridine_diazirine	[C,N]1~[C,N]~N~1
azo_amino	[N]=[N;!R]-[N]
azo_aryl	c[N;!R;!+]=[N;!R;!+]-c
azo_filter1	[N;!R]=[N;!R]-[N]=[*]
azu_iiilei i	[[x,:x]-[x,:x]-[x]=[]

Filter	SMARTS
azo_filter2	[N;!\$(N-S(=O)(=O));!\$(N-C=O)]-[N;!r3;!\$(N-S(=O)(=O));!\$(N-C=O)]-[N;!\$(N-S(=O)(=O));!\$(N-C=O)]
azo_filter3	[N;!R]-[N;!R]
azo_filter4	a-N=N-[N;H2]
azoalkanal	[N;R0]=[N;R0]CC=O
azocyanamide	[N;R0]=[N;R0]C#N
bad_boron	[B-,BH2,BH3,\$(B(F)(F))]
bad_cations	[C+,F+,Cl+,Br+,l+,Se+]
b-	
carbonyl_quaternary_nitrogen	C(=O)CC[N+,n+]
benzhydrol	[OH1]-C(-c1ccccc1)-c2ccccc2
benzidine_like	c([N;!+])1ccc(c2ccc([N;!+])cc2)cc1
benzylic-quaternary_nitrogen	cC[N+]
beta_lactam	C1(=O)~[#6]~[#6]N1
beta_lactone	[#6,#15,#16]1(=O)~[#6]~[#8,#16]1
	C1(=O)~[#6]~[#6]N1([\$(S(=O)(=O)[C,c,O&D2]),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
betalactam_EWG]),\$(C(=O)[C,c,O&D2])])
	O=[C,S]Oc1aaa([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
]),\$(C(=O)O),\$(C(=O)N)])aa([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
bis_activated_aryl_ester]),\$(C(=O)O),\$(C(=O)N)])1
bis_keto_olefin	CC(=O)[\$([C&H1]),\$(C-F),\$(C-Cl),\$(C-Br),\$(C-I)]=[\$([C&H1]),\$(C-F),\$(C-Cl),\$(C-Br),\$(C-I)]C(=O)C
boron_wAr-Head	[C,c]~[#5]
branched_polycyclic_aromatic	a1(a2aa(a3aaaaa3)aa(a4aaaaa4)a2)aaaaaa1
carbazide	O=*N=[N+]=[N-]
carbodiimide_isothiocyanate	N=C=[N,O,S]
carbonyl_halide	O=C[F,Cl,Br,I]
chloramidine	[CI]C([C&R0])=N
	[\$([O,S,#7;R1;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r
	9,r10,r11,r12,r13,r14,r15,r16,r17,r18][O,S,#7;R1;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,
	r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][O,S,#7;R1;r9,r10,r11,r12,r13,r14,r15,r1
	6,r17,r18]),\$([O,S,#7;R1;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][
	CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][O,S,#7;R1;r9,r1
	0,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r1
	4,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][O,S,#7;R1;r9,r10,r11,r12,r13,r14,r15,r16,r17,
	r18]),\$([O,S,#7;R1;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,C
	H2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][O,S,#7;R1;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11
	r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18][CH,CH2;r9,r10,r11,r12,r13,r14,r15
crown_ether	,r16,r17,r18][O,S,#7;R1;r9,r10,r11,r12,r13,r14,r15,r16,r17,r18])]
cyanamide	N[CH2]C#N
cyanidin	[OH]c1cc([OH])cc2=[O+]C(=C([OH])Cc21)c3cc([OH])c([OH])cc3
cyano_phosphonate	P(O[A,a])(O[A,a])(=O)C#N
cyanohydrin	[C;X4](-[OH,NH1,NH2,SH])(-C#N)
cyanophosphonate	P(OCC)(OCC)(=O)C#N
cycloheximide	O=C1CCCC(N1)=O
cytochalasin	O=C1NCC2CCCC21
di_tri_phosphate	P(=O)([OH])OP(=O)[OH]
diamino_sulfide	[N,n]~[S;!R;D2]~[N,n]
diazo_carbonyl	[\$(N=N=C~C=O),\$(N#N-C~C=O)]
diazonium	a[N+]#N
dicarbonyl_sulfonamide	[\$(N(-C(=O))(-C(=O))),\$(n([#6](=O))([#6](=O))([#16](=O)))]

Filter	SMARTS
dihydroxybenzene	[OH1]c1ccc([OH1])cc1
disulfide	SS
disulfide_acyclic	[S;!R;X2]-[S;!R;X2]
disulfonyliminoquinone	S(=O)(=O)N=C1C=CC(=NS(=O)(=O))C=C1
double_trouble_wAr-Head	NC(C[S;D1])C([N;H1]([O;D1]))=O
epoxide_aziridine_thioepoxide	[CH2]1[O,S,N]C1
flavanoid	O=C2CC(a3aaaaaa3)Oa1aaaaaa12
four_nitriles	C#N.C#N.C#N
free_thiol	[SH]
	[#7,#8,#16]1[#6]([\$(S(=O)(=O)),\$([F,C]),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
]),\$(C(=O))])[#6]([\$(S(=O)(=O)),\$([F,CI]),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
halo_5heterocycle_bis_EWG]),\$(C(=O))])[#7][#6]1([CI,Br,I])
·	[\$([C;H2]),\$([C&H1\$(C-F)]),\$([C&H1\$(C-CI)]),\$([C&H1\$(C-Br)]),\$([C&H1\$(C-Br)]),\$([C&H1\$(C-Br)]),\$([C&H1S(C-Br)]),\$(
	I)]),\$(C(F)F),\$(C(Cl)Cl),\$(C(Br)Br),\$(C(I)I),\$(C(F)Cl),\$(C(F)Br),\$(C(F)I),\$(C(Cl)Br),\$(C(Br)I)](=[\$([C&H1\$(C(-
halo_acrylate	$C(=O)))]),\\\\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$
halo_imino	C(=[#7])([Cl,Br,l,\$(O(S(=O)(=O)))])
	C([Cl,Br,l,\$(O(S(=O)(=O)))])=C([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
halo_olefin_bis_EWG]),\$(C=O)])([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-]),\$(C=O)])
halo_phenolic_carbonyl	C(=O)Oc1c([Cl,F])[cH1,\$(c[F,Cl])]c([F,Cl])[cH1,\$(c[F,Cl])]c1([F,Cl])
halo_phenolic_sulfonyl	S(=O)Oc1c([Cl,F])[cH1,\$(c[F,Cl])]c([F,Cl])[cH1,\$(c[F,Cl])]c1([F,Cl])
halogen_heteroatom	[!C;!c;!H][F,Cl,Br,I]
hemiacetal	[#6]-O[CH1](-[#6])[OH1]
hetero_silyl	[Si]-[!#6]
heteroaryl_sulfonate	a-S(=O)(=O)-O-[\$([a&!#6]),\$(c[a&!#6]),\$(cc[a&!#6]),\$(ccc[a&!#6]),\$(cccc[a&!#6])]
HOBT_ester	O=C(-[!N])O[\$(nnn),\$([#7]=[#7])]
hydrazine2	[#7]! @-N! @=C
riyuraziriez	[N;X3;1\$(N-C(=O));!\$(N-C(F)(F)(F));!\$(N-C#N);!\$(N-C(=O));!\$(N-C(=S));!\$(N-C(=N))]-[N;X3;!*[N-C(=N)]-[N]-[N]-[N]-[N]-[N]-[N]-[N]
hydrazina	S(=O)(=O));!\$(N-C(F)(F)(F));!\$(N-C#N);!\$(N-C(=O));!\$(N-C(=N))]
hydrazine hydrazothiourea	
•	[N;!R]=NC(=S)N
hydroxamate_wAr-Head	C([N;H1]([O;D1]))=O
hyperval_sulfur	[\$([#16&D3]),\$([#16&D4])]=,:[#6]
Imine1	[#6;R0]C([#6;R0])=[NH1]
Imine2	[#6;R0][CH1]=[NH1]
isonitrile	[N+]#[C-]
Lawesson_reagent_derivative	
S	P(=S)(S)S
	[\$(a12aaaaa1aa3a(aa(aaaa4)a4a3)a2),\$(a12aaaaa1aa3a(aaa4a3aaaa4)a2),\$(a12aaaaaa1a(aa5)a3a(aaa4a3a
linear_polycyclic_aromatic_l	5aaa4)a2)]
	[\$(a12aaaa4a1a3a(aaaa3aa4)aa2),\$(a12aaaaaa1a3a(aaa4a3aaaa4)aa2),\$(a1(a(aaaa4)a4a3a2aaaa3)a2aaaa
linear_polycyclic_aromatic_II	1)]
maleimide_etc	[\$([C;H1]),\$(C(-[F,Cl,Br,l]))]1=[\$([C;H1]),\$(C(-[F,Cl,Br,l]))]C(=O)[N,O,S]C(=O)1
meldrums_acid_etc	O=C1OC(C)(C)OC(C1)=O
	[\$([Ru]),\$([Mg]),\$([Rh]),\$([Se]),\$([Se]),\$([Pd]),\$([Sc]),\$([Bi]),\$([Sb]),\$([Ag]),\$([Ti]),\$([Al]),\$([Cd]),\$([In
	Cr]),\$([Sn]),\$([Mn]),\$([La]),\$([Fe]),\$([Fr]),\$([Tm]),\$([Yb]),\$([Lu]),\$([Hf]),\$([Ta]),\$([W]),\$([Re]),\$([Co]),\$([Os]),\$([
	Ni]),\$([Ir]),\$([Cu]),\$([Zn]),\$([Ga]),\$([Ge]),\$([As]),\$([as]),\$([Y]),\$([Zr]),\$([Nb]),\$([Ce]),\$([Pr]),\$([Nd]),\$([Sm]),\$([Eu
]),\$([Gd]),\$([Tb]),\$([Dy]),\$([Ho]),\$([Pt]),\$([Au]),\$([Hg]),\$([Tl]),\$([Ac]),\$([Ac]),\$([Th]),\$([Pa]),\$([Mo]),\$([U]),\$([Tc])
metal	,\$([Te]),\$([Po]),\$([At])]
michael_acceptor6	[#6,#7]-&!@[#6](=&!@[CH])-&!@C(=O)-&!@[C,N,O,S]

Filter	SMARTS
michael_acceptor5	N#CC(=C)C#N
michael_acceptor_misc	O=C1[O,N]C~[N,C]C1=[C,N]
michael_acceptor_misc2	*~\C=C1/CC2=CC=C2N1
michael_acceptor_vinyl2	[CH2]=C-C(=O)-[#6,#7,#8]
misc_10_carbon_sb_chain	[C;!R]-[C;!R]-[C;!R]-[C;!R]-[C;!R]-[C;!R]-[C;!R]-[C;!R]-[C;!R]
misc_2_free_phos	P([O;D1])=O.P([O;D1])=O
misc_2_N_quats	[N,n;H0;+;!\$(N~O);!\$(n~O)].[N,n;H0;+;!\$(N~O);!\$(n~O)]
misc_2_sulfonic_acid	[C,c]S(=O)(=O)[O;D1].[C,c]S(=O)(=O)[O;D1]
misc_3_COOH	C(=O)[O;D1].C(=O)[O;D1].
misc_3_iodine	[#53].[#53].[#53]
	[N;!\$(N(=[N,O,S,C]));!\$(N(S(=O)(=O)));!\$(N(C(F)(F)(F)));!\$(N(C#N));!\$(N(C(=O)));!\$(N(C(=S)));!\$(N(C(=N)));!
	N(#C));!\$(N-
	$ c)].[N;!\$(N(=[N,O,S,C]));!\$(N(S(=O)(=O)));!\$(N(C(F)(F)(F)));!\$(N(C\#N));!\$(N(C(=O)));!\$(N(C(=S)));!\$(N(C(=N)))))))] \\ (-1)[N;!\$(N(=[N,O,S,C]));!\$(N(S(=O)(=O)));!\$(N(C(F)(F)(F)(F)));!\$(N(C\#N));!\$(N(C(=O)));!\$(N(C(=N))))))) \\ (-1)[N;!\$(N(C(=O)(=O)));!\$(N(C(E)(E)(E)(E)(E)(E)(E)(E)(E)(E)(E)(E)(E)($
	;!\$(N(#C));!\$(N-
	c)].[N;!\$(N(=[N,O,S,C]));!\$(N(S(=O)(=O)));!\$(N(C(F)(F)(F)));!\$(N(C#N));!\$(N(C(=O)));!\$(N(C(=S)));!\$(N(C(=N))))))]
	;!\$(N(#C));!\$(N-
	c)].[N;!\$(N(=[N,O,S,C]));!\$(N(S(=O)(=O)));!\$(N(C(F)(F)(F)));!\$(N(C#N));!\$(N(C(=O)));!\$(N(C(=S)));!\$(N(C(=N)))
misc_4_basic_N	;!\$(N(#C));!\$(N-c)]
antan Allahan	[\$([N+](=O)[O-]),\$(N(=O)=O)].[\$([N+](=O)[O-]),\$(N(=O)=O)].[\$([N+](=O)[O-]),\$(N(=O)=O)].
misc_4_nitro]),\$(N(=O)=O)]
misc_5_phenolic_OH	a[O;D1].a[O;D1].a[O;D1].a[O;D1]
misc_7_aliphatic_OH	C[O;D1].C[O;D1].C[O;D1].C[O;D1].C[O;D1].C[O;D1].
misc_7_total_hal	[CI,Br,I].[CI,Br,I].[CI,Br,I].[CI,Br,I].[CI,Br,I].[CI,Br,I].[CI,Br,I]
misc_8_CF2_or_CH2	[CH2,\$(CF2);R0][CH2,\$(CF2);R0][CH2,\$(CF2);R0][CH2,\$(CF2);R0][CH2,\$(CF2);R0][CH2,\$(CF2);R0][CH2,\$(CF2);R0][CH2,\$(CF2);R0][CH2,\$(CF2);R0][CH2,\$(CF2);R0]
monensin	01CCCC1C2CCC02
monofluoroacetate	[C;H2](F)C(=0)[O,N,S]
nitrate	[#6]-O-[N+](=O)[O-]
nitro_aromatic	(a-[N+](=O)[O-].a-[N+](=O)[O-])
nitroalkane	C[N+](=O)[O-]
nitrone	[C;IR]=[N+][O;D1]
nitrosamine	N-[N;X2](=O)
nitroso	[N&D2](=O)
NO_phosphonate	P(=O)ON
ortho_hydroiminoquinone	c1c([N;D1])c([N;D1])c[cH1][cH1]1
ortho_hydroquinone	a1c([O,S;D1])c([O,S;D1])a[cH1][cH1]1
ortho_nitrophenyl_carbonyl	[#6]1(-O-[C;!R](=[O,N;!R]))[#6]([\$(N(=O)(=O)),\$([N+](=O)[O-])])[#6][#6][#6]1
ortho_quinone	[CH1,\$(C(-[Cl,Br,l]))]1=CC(=[O,N,S;!R])C(=[O,N,S])C=[CH1,\$(C(-[Cl,Br,l]))]1
oxaziridine	C1~[0,S]~N1
oxime	[\$(C=N[O;D1]);!\$(C=[N+])][#6]
oxonium	[o+,O+]
P_S_halide	[P,S][F,Cl,Br,l]
para_hydroiminoquinone	a1[cH1]c([N;D1])[cH1]ac([N;D1])1
para_hydroquinone	a1[cH1]c([O,S;D1])[cH1]ac([O,S;D1])1
para_nitrophenyl_ester	[#6]1(-O(-[C;!R](-[!N])(=[O,N;!R])))[#6][#6][#6]([\$(N(=O)(=O)),\$([N+](=O)[O-])])[#6][#6]1
	[CH1,\$(C(-[CI,Br,I]))]1=[CH1,\$(C(-[CI,Br,I]))]C(=[O,N,S])[CH1,\$(C(-[CI,Br,I]))]=[CH1,\$(C(-
para_quinone	[Cl,Br,l]))]C1(=[O,N,S])
paraquat_like	[#6]1[#6]([#6]2[#6][#7;+][#6][#6]2)[#6][#7;+]1

Filter	SMARTS
pentafluorophenylester	C(=O)Oc1c(F)c(F)c(F)c(F)c(F)
perchloro_cp	C1(CI)(CI)C(CI)=C(CI)C1(CI)
perhalo_dicarbonyl_phenyl	c1(C=O)c([Br,Cl,I])c([Br,Cl,I])c([Br,Cl,I])c1(C=O)
perhalo_ketone	O=CC(-[F,Cl,Br,I])(-[F,Cl,Br,I])-[F,Cl,Br,I]
perhalo_phenyl	c1c([F,Br,Cl,I])c([F,Br,Cl,I])c([F,Br,Cl,I])c([F,Br,Cl,I])c1([F,Br,Cl,I])
peroxide	[#8]~[#8]
	O=[C,S]Oc1aaa([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-
	$]), \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$
phenolate_bis_EWG]),\$(C(=O)O),\$(C(=O)N)])1
phos_serine_wAr-Head	NC(COP(O)(O)=O)C(O)=O
phos_threonine_wAr-Head	NC(C(C)OP(O)(O)=O)C(O)=O
phos_tyrosine_wAr-Head	NC(Cc1ccc(OP(O)(O)=O)cc1)C(O)=O
phosphite	[c,C]-[P;v3]
phosphonate_esters	COP(=O)(=O)[C,c]
phosphonium	[#15;+]~[!O]
phosphoramide	NP(=O)(N)N
phosphorane	C=P
phosphorous_nitrogen_bond	[#15]~[N,n]
phosphorus_phosphorus_bon	
d	P~P
phosphorus_sulfur_bond	P~S
polyacidic4	[C,S,P](=O)[OH].[C,S,P](=O)[OH].[C,S,P](=O)[OH]
polyazoanthracene	c12:[c,n]:[c,n]:[c,n]:[c,n]:c1[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:c3[c,n]2
polyazophenanthrene	c12:[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:[c,n]:c23
polyene	C=[C;!R][C;!R]=[C;!R]=[C;!R]
polyhalo_phenol_a	c1c([O;D1])c(-[Cl,Br,l])c(-[Cl,Br,l])cc1.c1c([O;D1])c(-[Cl,Br,l])c(-[Cl,Br,l])cc1
polyhalo_phenol_b	c1c([O;D1])c(-[Cl,Br,l])cc(-[Cl,Br,l])c1.c1c([O;D1])c(-[Cl,Br,l])cc(-[Cl,Br,l])c1
polyhalo_phenol_c	c1c([O;D1])ccc(-[Cl,Br,l])c(-[Cl,Br,l])1.c1c([O;D1])ccc(-[Cl,Br,l])c(-[Cl,Br,l])1
polyhalo_phenol_d	c(-[Cl,Br,l])1c([O;D1])c(-[Cl,Br,l])ccc1.c(-[Cl,Br,l])1c([O;D1])c(-[Cl,Br,l])ccc1
polyhalo_phenol_e	c1c([O;D1])ccc(-[Cl,Br,l])c(-[Cl,Br,l])1.c1c([O;D1])ccc(-[Cl,Br,l])c(-[Cl,Br,l])1
polysulfide	[S;D2]-[S;D2]
porphyrin	[#6;r16,r17,r18]~[#6]~[#6]~[#6]~[#6](~[#6])~[#7]1
primary_halide_sulfate	[CH2][Cl,Br,l,\$(O(S(=O)(=O)[!\$(N);!\$([O&D1])]))]
propiolactone	C1(=0)OCC1
quat_N_acyl	[N,n;+]! @C(=O)
quat_N_N	[N,n;R;+]! @[N,n]
quaternary_C_CI_I_P_S	[C+,Cl+,l+,P+,S+]
quaternary_nitroxy	C[N+](-[O-])(C)C
	[#6;!\$([#6](-[N,O,S]))]1=[#6;!\$([#6](-[N,O,S]))][#6](=[#6])[#6;!\$([#6](-[N,O,S]))]=[#6;!\$([M,O,S]))]=[#6;!\$([M,O,S])]=[#6;!\$([M,O,S])]=[#6;!\$([M,O,S])]=[#6;!\$([M,O,S])]=[#6;!\$([M,O,S])]=[#6;!\$([M,O,S])]=[#6;!\$([M,O,S])]=[#6;!]
quinone_methide	[N,O,S]))][#6]1(=[O,N,S])
rhodanine	C(=C)1SC(=S)NC(=O)1
secondary_halide_sulfate	[CH;!\$(C=C)][CI,Br,I,\$(O(S(=O)(=O)[!\$(N);!\$([O&D1])]))]
squalestatin	C12OCCC(O1)CC2
sulf_D2_nitrogen	[S;D2](-[N;!\$(N(=C));!\$(N(-S(=O)(=O)));!\$(N(-C(=O)))])
sulf_D2_oxygen_D2	[S;D2][O;D2]
sulf_D3_nitrogen	[S;D3](-N)(-[c,C])(-[c,C])
sulfite_sulfate_ester	[C,c]OS(=O)O[C,c]
sulfonate	COS(=O)(=O)[C,c]

Filter	SMARTS		
sulfonium	[S+;X3;\$(S-C);!\$(S-[O;D1])]		
sulfonyl_anhydride	[\$(C(=O)),\$(S(=O)(=O))][O,S](S(=O)(=O))		
sulfonyl_halide	S(=O)(=O)[F,Cl,Br,I]		
sulfonyl_heteroatom	[!#6;!#1;!#11;!#19]O(S(=O)(=O)(-[C,c]))		
sulphonyl_cyanide	S(=O)(=O)C#N		
tertiary_halide_sulfate	[C;X4](-[Cl,Br,l,\$(O(S(=O)(=O)[!\$(N);!\$([O&D1])]))))(-[c,C])(-[c,C])		
thio_hydroxamate	[S;D2]([\$(N(=C)),\$(N(-S(=O)(=O))),\$(N(-C(=O)))])		
thio_xanthate	[S;!R]-[C;!R](=[S;!R])(-[S;!R])		
thioamide	[#6]C([#7H2])=S		
thiocarbonate	SC(=O)[O,S]		
thiocyanate	SC#N		
thioester	[S;!R;H0]C(=[S,O;!R])([!O;!S;!N])		
thioketone	CC(=S)C		
thiol_wAr-Head	NC(C[S;D1])C(O)=O		
thiopyrylium	c1[S,s;+]cccc1		
thiosulfoxide	[C,c][S;X3](~O)-S		
thiourea	C([#7H2])([#7H2])=S		
tri_phosphoric_esters	([#6]OP(=O)(-*)O[#6].[#6]OP(=O)(-*)O[#6].[#6]OP(=O)(-*)O[#6])		
triacyloxime	C(=O)N(C(=O))OC(=O)		
triamide	[\$(N(-C(=O))(-C(=O))),\$(n([#6](=O))([#6](=O))([#6](=O)))]		
triaryl_phosphine_oxide	P(=O)(a)(a)(a)		
trichloromethyl_ketone	[\$(C(=O));!\$(C-N);!\$(C-O);!\$(C-S)]C(Cl)(Cl)(Cl)		
triflate	OS(=O)(=O)(C(F)(F)(F))		
trifluoroacetate_ester	C(F)(F)(F)C(=O)O		
trifluoroacetate_thioester	C(F)(F)(F)C(=O)S		
trifluoromethyl_ketone	[\$(C(=O));!\$(C-N);!\$(C-O);!\$(C-S)]C(F)(F)		
trihalovinyl_heteroatom	C(-[CI,Br,I])(-[CI,Br,I])=C(-[CI,Br,I])(-[N,O,S])		
	[\$(a1aaa([\$(N(=O)(=O)),\$([N+](=O)[O-])])a([\$(N(=O)(=O)),\$([N+](=O)[O-])])a1([\$(N(=O)(=O)),\$([N+](=O)[O-])])a1([\$(N(=O)(=O)),\$([N+](=O)(=O))]a1([S(N(=O)(=O)),\$([N+](=O)(=O))]a1([S(N(=O)(=O)),\$([N+](=O)(=O))]a1([S(N(=O)(=O)),\$([N+](=O)(=O))]a1([S(N(=O)(=O)),\$([N+](=O)(=O))]a1([S(N(=O)(=O)(=O)),\$([N+](=O)(=O))]a1([S(N(=O)(=O)(=O)(=O)),\$([N+](=O)(=O)(=O))]a1([S(N(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)		
	$])])),\\\\ (a1aa([\$(N(=O)(=O)),\$([N+](=O)[O-])])a([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)[O-])])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)(=O)),\$([N+](=O)(=O))])aa1([\$(N(=O)(=O)(=O)(=O))])aa1([\$(N(=O)(=O)(=O)(=O)(=O)(=O))])aa1([\$(N(=O)(=O)(=O)(=O)(=O)(=O)(=O))])aa1([\$(N(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)(=O)$		
	$])])),\\$		
trinitro_aromatic	1)1))]		
trinitromethane_derivative	C([\$([N+](=O)[O-]),\$(N(=O)=O)])([\$([N+](=O)[O-]),\$(N(=O)=O)])([\$([N+](=O)[O-]),\$(N(=O)=O)])		
	[\$(O=[C,S]Oc1a([\$(S(=O)(=O)),F,\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-		
	$]), \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$		
	$]), \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$		
]),\$(C(=O)O),\$(C(=O)N)])aa1),\$(O=[C,S]Oc1a([\$(S(=O)(=O)),F,\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)		
	$[O-]), \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\ \\$		
]),\$(C(=O)O),\$(C(=O)N)])aaa([\$(S(=O)(=O)),F,\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-		
]),\$(C(=O)O),\$(C(=O)N)])1),\$(O=[C,S]Oc1a([\$(S(=O)(=O)),F,\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O		
	-]),\$(C(=O)O),\$(C(=O)N)])aa([\$(S(=O)(=O)),F,\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-I),\$(C(-O)(-O)(-O)(-O)(-O)(-O)(-O)(-O)(-O)(-O)		
]),\$(C(=O)O),\$(C(=O)N)])a([\$(S(=O)(=O)),F,\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-I),\$((O)(-O)(-O)(I),I),\$((O)(-O)(-O)(I),I),\$((O)(-O)(-O)(I),I),\$((O)(-O)(-O)(I),I),\$((O)(-O)(-O)(I),I),\$((O)(-O)(-O)(I),I),\$((O)(-O)(-O)(I),I),\$((O)(-O)(-O)(I),I),\$((O)(-O)(I),I),\$((O)(-O)(I),I),\$((O)(-O)(I),I),\$((O)(-O)(I),I),\$((O)(I),I),\$(
]),\$(C(=O)O),\$(C(=O)N)])a1),\$(O=[C,S]Oc1a([\$(S(=O)(=O)),F,\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[
	O-]), $\$(C(=O)O)$, $\$(C(=O)N)$])aa([$\$(S(=O)(=O))$, F , $\$(C(F)(F)(F))$, $\$(C\#N)$, $\$(N(=O)(=O))$, $\$([N+](=O)[O-1)$, $\$(C(=O)O)$, $\$(C(=O)N)$])aa([$\$(S(=O)(=O))$, F , $\$(C(F)(F)(F)$), $\$(C\#N)$, $\$(N(=O)(=O))$, $\$([N+](=O)[O-1]$		
tris_activated_aryl_ester]),\$(C(=O)O),\$(C(=O)N)])aa([\$(S(=O)(=O)),F,\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-]),\$(C(=O)O),\$(C(=O)N)]]1)]		
uis_activateu_aryi_ester]),\$(C(=O)O),\$(C(=O)N)])1)] [[CH;!R];!\$(C-N)]=C([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-		
trisub_bis_act_olefin	[[CH, K], (C+V)] = C([S(S(=O)(=O)), S(C(F)(F)(F)), S(C+N), S(N(=O)(=O)), S([N+](=O)[O-]), S(C(=O))]) $[]N, S(C(=O))]N([S(S(=O)(=O)), S(C(F)(F)(F)), S(C+N), S(N(=O)(=O)), S([N+](=O)[O-]), S(C(=O))])$		
unacceptable_atoms1	[!#6;!#7;!#8;!#16;!#1;!#3;!#9;!#11;!#12;!#15;!#17;!#19;!#20;!#30;!#35]		
unacceptable_atoms2	[!#6;!#7;!#8;!#16;!#1;!#3;!#9;!#11;!#12;!#15;!#17;!#19;!#20;!#30;!#35]		
anacceptable_atoms2	[[[[]], []], []], [[]], [[]], []], [[

Filter	SMARTS	
	[C;!R]([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-	
]),\$(C=O)])([\$(S(=O)(=O)),\$(C(F)(F)(F)),\$(C#N),\$(N(=O)(=O)),\$([N+](=O)[O-	
vinyl_carbonyl_EWG]),\$(C=O)])=[C;!R]([C;!R](=O))([!\$([#8]);!\$([#7])])	
vinyl_sulfone	O=S([#6]=[#6])([#6]=[#6])=O	
vinyloxazole	[N,C]=CC1=COC=N1	
2,3,4-trihydroxyphenyl	c([OH])c([OH])c([OH])	

Table S3. Undesirable functionality SMARTS definitions utilised by the NIH.¹

thiocarbonyl [
	[c,C]=[S;X1]	
termalkyne [[CH]#C	
quinonepara	O=[#6]1[#6]~[#6](#6](=O)[#6]~[#6]1	
nonpeptidic_macrocycl [[!R0!r3!r4!r5!r6!r7!r8!\$([N;!H0,\$(N1[CH2][CH2][CH2][CH1]1)][CH]C=O)!\$([CH]([N;!H0,\$(N1[CH2][CH2][CH1]1)])C=O)!\$([CH]([N;!H0,\$(N1[CH2][CH2][CH2][CH1]1)])C=O)!\$([CH]([N;!H0,\$(N1[CH2][CH2][CH2][CH2][CH2][CH2][CH2][CH2]	
e =	=O)!\$(C(=O)[CH][N;!H0,\$(N1[CH2][CH2][CH1]1)])]	
nitrogen_oxygen_bond *	*-[n,N]-[O;H0;R0]	
methyl_ester_x2 [[\$([CH3]OC=O)].[\$([CH3]OC=O)]	
imide	O=C([#6])NC(=O)[#6]	
exocyclic_double_bon		
d_toC [[R;#7,#8,#16,#6X3][R]=! @ C	
ethyl_ester_x2 [[\$([CH2](OC=O)[CH3])][CH3].[\$([CH2](OC=O)[CH3])][CH3]	
ester_deep_in_mol *	*[#6]C(=O)[O;R0][#6;\$(*(OC=O)**),\$(*(OC=O)(*)*)]	
enolether (C=!@C[OD2]	
conjugated_C=C	C=[C;R0][C;R0]=C	
benzyl_ester [[\$([CH2](OC=O)c1[cH][cH][cH][cH][cH][cH][cH][cH][cH][cH]	
aromatic_tricyclic1	c1ccc3c(c1)[C;!\$(C=O)]c2ccccc23	
allyl_ester [[\$([CH2](OC=O)[CH]=[CH2])][CH]=[CH2]	
alkylNandNonC 1	N[CX4]!@N	
alkCl [[C][C!!\$(CIC(CI)(CI))]	
alkBr	CBr	
acyclic_sulphur_micha		
el_acceptor [[C!\$(*[Nv3X3])]=! @[C!\$(*[Nv3X3])][S!\$(*[Nv3X3])]=O	
acyclic_imine [[C!\$(*(=N)[N,n])]=! @[Nv3!\$(*O)]	
acyclic_hydrazine [[Nv3X3!\$(*(C=O)NC=O)]-!@[Nv3X3!\$(*(C=O)NC=O)]	
acetyl_x2 [[CH3]C(=O)O.[CH3]C(=O)O	
acetal [[OX2;\$(OC[OX2])][C;!\$(C1(O)CNCCO1);!\$(C1(O)(CO)OC(CO)C(O)C1O);!\$(C1(O)OC(CO)C(O)C(O)C1O)][OX2][!a]	
OCO_protecting_grou		
р [[O;R0][C;X4][O;R0]	
N-SO_group	N[S;!\$(S(=O)(=O))]=O	
C=N=O_gp	C=N=O	
C(=O)CC(=O)_gp [[c,C]C(=O)[C!H0!R]C(=O)[C,c]	
4_fused_ring_sys [[R2][R3][R2][R2]	
C#C	C#C.C#C	
C#C-c_gp	cC#[C!H1]	
3_mem_ring_with_het [[S,O,N;r3]	
acylcarbamate (O=[S,C]NC(=O)O	
anyNO [[Nv3,n]=O	
phenol_x2 [[OH][c;\$(c1ccccc1)].[OH][c;\$(c1ccccc1)]	

formamide	[#7;!\$(N[OH])][CH1]=O
benzyl_halide	[CX4](a)[F,Cl,Br,l;!\$(FC(F)F)]

Table S4. Undesirable functionality SMARTS definitions that comprise the 'GSKB' filter.²

Filter		
Acyl halide	Disulfide	
Aldehyde	Hydrazine (terminal)	
Alkyl halide	Isocyanate	
Anhydride	Isothiocyanate	
Diazo	Peroxide	
Dicarbonyl	Quaternary ammonium	

 Table S5. Undesirable functionality filters used in the 'HTS Filter' embedded in Pipeline Pilot.

ZINC Da		ase (9046036)	Random 1% of ZINC Database (90911)		Virtual Library (1110)	
Filter	Successive Filtering	Parallel Filtering	Successive Filtering	Parallel Filtering	Successive Filtering	Parallel Filtering
Fail 14 ≤ nHA ≤ 26	4395739	4395739 (48%)	43971	43971 (48%)	173	173 (16%)
Fail –1 ≤ AlogP ≤ 3	1768807	4478982 (49%)	17828	44746 (49%)	200	220 (20%)
Fail Structural	819652	2805505 (31%)	8180	28147 (31%)	3	5 (0.5%)
Pass All	2061838 (23%)	n/a	20932 (23%)	n/a	734 (66%)	n/a

Table S6. Lead-likeness assessment data. For comparison, data obtained from parallel filtering of all compounds using each filter in isolation is also shown.

Scaffold	Number of Final Compounds	Number of Lead-like Compounds	% Lead-like Compounds
5a	64	62	97
5b	64	55	86
5c	116	68	59
5d	71	37	52
7a	76	62	82
7b	75	46	61
7c	127	47	37
8a	26	24	92
8c	78	39	50
8d	10	4	40
10a	26	24	92
10b	26	18	69
11d	37	31	84
13a	15	14	93
13b	15	14	93
13c	67	40	60
13d	21	7	33
14c	60	33	55
16a	8	7	88
16b	8	6	75

Scaffold	Number of Final Compounds	Number of Lead-like Compounds	% Lead-like Compounds
16c	60	58	97
16d	60	38	63
Total	1110	734	66

Table S7. Number of final compounds derived from each scaffold, together with the number and percentage of compounds that are lead-like (i.e. pass all filters).

Scaffold or Library	Mean Fsp³
ZINC (random 1%, 90911)	0.33
Virtual Library (1110)	0.57

Table S8. Mean Fsp³ data for the random 1% of the ZINC database and the virtual library of 1110 decorated final compounds.







Figure S6. Distribution of the number of heavy atoms (Num_Atoms) and AlogP for the 1110 decorated final compounds derived from the 22 scaffolds using the virtual library enumeration process (Figure S1). Compounds that survive successive filtering are shown in green (734 compounds, 66%). Compounds that fail successive filtering by number of heavy atoms (red, 173 compounds, 16%), AlogP (yellow, 200 compounds, 18%) and structural liabilities (black, 3 compounds, 0.3%) are shown.










Figure S7. Distribution of number of heavy atoms (Num_Atoms) and AlogP for the virtual library based upon each scaffold. Compounds that survive successive filtering are shown in green. Compounds that fail successive filtering by number of heavy atoms (red), AlogP (yellow) and structural features (black) are shown as appropriate.

5.0 Shape Analysis – Principal Moments of Inertia

3D structures were generated from the 2D Pipeline Pilot output using OpenEye OMEGA (OMEGA 2.4.3, OpenEye Scientific Software, 2010) and the lowest energy conformer was selected.⁴ The 3D structures were used to generate the three Principal Moments of Inertia (I₁, I₂ and I₃) using Accelrys Pipeline Pilot (Pipeline Pilot v8.5.0.200, Accelrys© Software Inc., 2011) which were then normalised by dividing the two lower values by the largest (I₁/I₃ and I₂/I₃). These Normalised PMI plots generate a triangular plot with the corners defined by a perfect sphere, a perfect disk and a perfect rod shape.⁵ We thank George Burslem for carrying out the PMI analysis.

6.0 Scaffold Diversity Assessment

The hierarchical framework analysis applied the 'scaffold tree' approach described by Schuffenhauer and co-workers.⁶ The results are summarized in Figure S8 and the frameworks illustrated in Figure S9. 22 frameworks were represented at the graph-node-bond level, ultimately related to 7 parental frameworks.




Figure S8. Hierarchical relationship between the 22 distinct molecular frameworks at the graph-node-bond level (black) and the 7 parental frameworks (blue). Daughter frameworks are shown in red.




Figure S9. The 22 distinct molecular frameworks at the graph-node-bond level (black) and the 7 parental frameworks (blue). Daughter frameworks are shown in red. The scaffolds which represent each framework are indicated. See Figure S8 for the relationship between scaffolds at each level of hierarchy.

7.0 Experimental

7.1 General experimental

All non-aqueous reactions were performed under an atmosphere of nitrogen unless otherwise stated. Water-sensitive reactions were performed in oven-dried glassware, cooled under nitrogen before use. THF, CH₂Cl₂, PhMe and MeCN were dried and purified by means of a Pure Solv MD solvent purification system (Innovative Technology Inc.). Anhydrous DMF was obtained in a SureSeal bottle from Sigma-Aldrich. All other solvents used were of chromatography or analytical grade. Petrol refers to petroleum spirit (b.p. 40-60 °C). Commercially available starting materials were obtained from Sigma-Aldrich, Fluka, Acros, Alfa-Aesar or Fluorochem and were used without purification.

Thin layer chromatography (TLC) was carried out on aluminium backed silica plates (Merck silica gel 60 F254). Visualisation of the plates was achieved using an ultraviolet lamp (λ_{max} = 254 nm) and KMnO₄. Flash chromatography was carried out using silica gel 60 (60-63 μ m particles) supplied by Merck. Columns with solvent gradients were carried out using a Biotage Flashmaster II on pre-packed Redisep normal-phase silica or cyanosilica cartridges (as specified). Strong cation exchange solid phase extraction (SCX-SPE) was carried out using pre-packed Discovery DSC-SCX cartridges supplied by Supleco, see General procedure **M**.

Optical rotation measurements were carried out at the sodium D-line (589 nm) on a Schmidt and Haensch H532; concentrations are in g/100 mL, temperatures are given in °C, optical rotations are given in deg dm⁻¹cm³ g⁻¹ (units are omitted). Infrared spectra were recorded on a Perkin-Elmer One FT-IR spectrometer with absorption reported in wavenumbers (cm⁻¹). High resolution mass spectra (HRMS) were recorded on a Bruker Daltonics micrOTOF or Bruker MaXis Impact spectrometer with electrospray ionisation (ESI) source. Where EI ionisation was required, a Waters/Micromass GCT Premier spectrometer was used.

Proton (1 H) and carbon (13 C) NMR spectral data were collected on a Bruker Advance 500 or Bruker DPX500 or DPX300 spectrometers. Chemical shifts (δ) are quoted in parts per million (ppm) and referenced to the residual solvent peak. Coupling constants (J) are quoted in Hertz (Hz) and splitting patterns reported in an abbreviated manner: app. (apparent), s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet). Assignments were made with the aid of COSY, DEPT-135, HMQC, HMBC and NOESY experiments. Compounds are numbered with respect to their IUPAC names. Where necessary, coloured text is used to distinguish similar protons and carbons. Diastereomeric ratios were calculated by analysis of the 1 H NMR spectra and assigned through the interpretation of coupling constants, NOESY spectra, and through crystallographic studies.

7.2 General procedures

General procedure A: Boc-carbamate deprotection

Boc-carbamate 1 (1.0 eq.) was diluted in 2:1 CH₂Cl₂—TFA (0.5 M) at 0 °C. The reaction mixture was stirred for 1 h at rt then concentrated *in vacuo*. The compounds **S2** were purified by SCX, according to General procedure **M**.

General procedure B: Cyclic carbamate synthesis

Following a procedure by Licini,⁷ iodine (3.0 eq.) was added to Boc-carbamate **1** (1.0 eq.) in 1:1 THF–H₂O (0.04 M, 1 volume) and the reaction mixture was stirred for 2-3 h. Sat. aq. Na₂S₂O₃ was added until the reaction mixture turned colourless. The reaction mixture was extracted with CH_2Cl_2 (2 × 0.25 volume). The organics were washed with brine (0.5 volume) then dried over Na₂SO₄, filtered, and concentrated *in vacuo* to give the crude iodide. The iodide was diluted in DMF (0.1 M, 1 volume) and NaN₃ (2.0 eq.) was added (*CAUTION*: azides are potentially explosive and should be handled with care – this reaction should be performed behind a blast shield. NaN₃ is extremely toxic and should be weighed out using a non-metal spatula inside a fumehood). The reaction mixture was stirred for 15 h. H₂O was added at 0 °C. The reaction mixture was extracted with EtOAc (3 × 0.25 volume). The organics were washed with brine then dried over Na₂SO₄, filtered, and concentrated *in vacuo*. Compounds **5** were purified by flash chromatography.

General procedure C: Carbamoyl urea synthesis

Following a procedure by Taguchi,⁸ ethyl isocyanatoformate (1.2 eq.) was added to a stirred solution of amino ester **S2** (1.0 eq.) in CH₂Cl₂ (0.1 M). The reaction mixture was stirred for 0.5 h then concentrated *in vacuo* to give the crude urea **6**.

General procedure D: Cyclic urea synthesis

Following a procedure by Taguchi,⁸ Li[Al(O'Bu)₄] (0.7 M in THF, 1.0 eq., prepared following general procedure **N**) was added to the crude urea **6** in PhMe (0.1 M, 1 volume) at -5 °C. The reaction mixture was stirred for 0.5 h, then iodine (3.0 eq.) was added. The reaction mixture was stirred for 15 h at -5 °C, then quenched with ice-cold sat. aq. Na₂S₂O₃ until colourless. The reaction mixture was extracted with ice-cold EtOAc (3 × 0.5 volume). The organics were dried over Na₂SO₄ at 0 °C, filtered, then concentrated *in vacuo* to give the crude iodide. The residue was dissolved in DMF (0.2 M, 1 volume) and NaN₃ (2.0 eq.) was added *(CAUTION: azides are potentially explosive and should be handled with care – this reaction should be performed behind a blast shield. NaN₃ is extremely toxic and should be weighed out using a non-metal spatula inside a fumehood). The reaction mixture was stirred for 15 h at rt. H₂O (0.5 volume) was added at 0 °C. The reaction mixture was extracted with EtOAc (3 × 0.25 volume). The organics were washed with brine then dried, filtered, and concentrated <i>in vacuo*. Compounds **7** were purified by flash chromatography.

General procedure E: Hydantoin synthesis

NaOMe (25 wt% in MeOH, 1.0 eq.) was added to the crude urea **6** in 85:15 PhMe–MeOH (0.1 M). The reaction mixture was heated at 65 °C for 2 h, then concentrated *in vacuo*. Compounds **8** were purified by SCX eluting with MeOH.

General procedure F: Reductive amination with N-Boc glycinal

A suspension of amino ester **\$2** (1.0 eq.), *N*-Boc glycinal (2.0 eq.) and 4 Å MS (50 mg for 2.5 mmol of amine) in CH₂Cl₂ (0.1 M, 1 volume) was stirred for 1 h. NaBH(OAc)₃ (2.0 eq.) was added in one portion and the reaction mixture was stirred for 15 h. The reaction mixture was filtered through Celite then concentrated *in vacuo*. The residue was dissolved in EtOAc (0.5 volume) and washed with brine (0.5 volume). The aqueous phase was extracted with EtOAc (2 × 0.25 volume). The combined organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. Compounds **9** were carried on crude without further purification.

General procedure G: Lactamisation

The crude *N*-Boc glycinated amino ester $\bf 9$ (1.0 eq.) was deprotected, following general procedure $\bf A$. The residue was diluted in DMF (0.04 M) and Cs₂CO₃ (2.0 eq.) was added. The reaction mixture was heated at reflux for 1 h, then concentrated *in vacuo*. The compounds $\bf 10$ were purified by flash chromatography or by SCX, according to General procedure $\bf M$.

.

General procedure H: Reductive amination with 2-bromobenzaldehyde

A suspension of amino ester **\$2** (1.0 eq.), 2-bromobenzaldehyde (2.0 eq.) and 4 Å MS (50 mg for 2.5 mmol of amine) in CH₂Cl₂ (0.1 M) was stirred for 1 h. NaBH(OAc)₃ (2.0 eq.) was added in one portion and the reaction mixture was stirred for 15 h. The reaction mixture was filtered through Celite then concentrated *in vacuo*. The residue was dissolved in EtOAc (0.5 volume) and washed with brine (0.5 volume). The aqueous phase was extracted with EtOAc (2 × 0.25 volume). The combined organic phase was dried over MgSO₄, filtered, and concentrated *in vacuo*. Compounds **12** were purified by flash chromatography or by SCX, according to General procedure **M**.

General procedure I: Intramolecular Heck reaction

Et₃N (2.5 eq.) was added to a stirred solution of amino ester **12** (1.0 eq.) and Pd(PPh₃)₄ (5 mol%) in MeCN (0.1 M). The mixture was heated at 125 °C under microwave irradiation for 1 h, then filtered through Celite and concentrated *in vacuo*. Compounds **13** were purified by flash chromatography.

General procedure J: N-Allylation of amines

Allyl bromide (3.0 eq.) and K_2CO_3 (1.1 eq.) were added to a stirred solution of amino ester **S2** (1.0 eq.) in DMF (0.2 M, 1 volume) and the reaction mixture was stirred for 15 h. The reaction mixture was diluted with H_2O (0.5 volume) and extracted with EtOAc (3 × 0.25 volume). The organics were washed with brine (0.5 volume) then dried over MgSO₄, filtered, and concentrated *in vacuo*. The compounds **15** were purified by SCX, according to General procedure **M**.

General procedure K: Ring-closing metathesis

$$R$$
 CO_2Me N R CO_2Me

Following a procedure by Gracias *et al.*, 9 *p*-TsOH (2.0 eq.) was added to a stirred solution of *N*-allyl amino ester **15** (1.0 eq.) in CH₂Cl₂ or PhMe as specified (0.03 M, 1 volume). The reaction mixture was heated at reflux for 0.5 h then cooled to rt. GII (2.5-7.5 mol%) was added, the mixture was heated at reflux and monitored by NMR until complete consumption of the starting material was observed. The reaction mixture was cooled to rt. Sat. aq. NaHCO₃ solution (0.25 volume) was added. The reaction mixture was extracted with CH₂Cl₂ (for reactions performed in CH₂Cl₂, 2×0.25 volume) or EtOAc (for reactions performed in PhMe, 2×0.25 volume). The organic phase was washed with brine, dried over Na₂SO₄, filtered, then concentrated *in vacuo*. Compounds **16** were purified by flash chromatography or by SCX, according to General procedure **M**.

General procedure L: Allylation of Boc-protected amino esters

LiHMDS (1.0 M in THF, 1.1 eq.) was added dropwise to a stirred solution of Boc-protected amino ester **S1** (1.0 eq.) in THF (0.45 M, 1 volume) at −78 °C. The reaction mixture was stirred for 15 min, then allyl bromide (1.5 eq.) was added dropwise. The reaction mixture was stirred for 1 h, the dryice bath was removed and the reaction mixture was warmed to rt and stirred for 15 h. Sat. aq. NH₄Cl solution (0.1 volume) was added, then the reaction mixture was partitioned between EtOAc (1 volume) and brine (1 volume). The aqueous layer was extracted with EtOAc (2 x 1 volume). The combined organic extracts were dried over MgSO₄ and concentrated *in vacuo*. Compounds **1** were purified by flash chromatography.

General procedure M: SCX purification

TfOH (0.5 M in MeOH, 10 mL / 5 g SPE-SCX) was dripped through the SPE-SCX cartridge prior to use. MeOH (20 mL) was then flushed through using pressurised air (bellows). The crude residue was loaded (3.5 mmol / 5 g SPE-SCX silica) in the minimum amount of MeOH. The cartridge was flushed with MeOH and the fractions were collected and monitored by TLC. The cartridge was then

flushed with sat. NH₃/MeOH and the fractions were collected and monitored by TLC. Fractions containing product were combined and concentrated.

General procedure N: Preparation of a Li[Al(O'Bu)4] solution in THF

t-BuOH (4.0 eq.) was added dropwise to LiAlH₄ in THF (1.0 M solution) at 0 °C (*CAUTION: gas evolution*). The reaction mixture was stirred for 0.5 h warming to rt and was considered to constitute a 0.7 M solution of Li[Al(O^tBu)₄].

7.3 Experimental data

1-tert-Butyl 2-methyl 2-(prop-2-en-1-yl)pyrrolidine-1,2-dicarboxylate 1a

N CO₂Me

General procedure **L** was followed using Boc-protected amino ester **S1a** (2.50 g, 10.9 mmol). Flash chromatography eluting with pentane–EtOAc (5:1) gave the title compound **1a** (2.4 g, 8.8 mmol, 81%) as a colourless oil. **R**_f 0.35 (4:1 petrol–EtOAc). **1H NMR** (300 MHz, CDCl₃, 1:2 mixture of rotamers): δ 5.89-5.64 (1H, m, C*H*=CH₂), 5.22-5.05 (2H, m, CH=C*H*₂), 3.76-3.54 (4H, includes 1H, m, 5-H_A and at δ 3.72: 3H, s, 60-3.28 (1H, m, 5-H_B), 3.11 (0.33H, dd, *J* 14.1, 6.5, C*H*_AH_BCH=CH₂), 2.92 (0.67H, dd, C*H*_AH_BCH=CH₂), 2.61 (1H, dd, *J* 14.1, 8.1, CH_AH_BCH=CH₂), 2.20-1.96 (2H, m, 3-H), H, m, 4-H), 1.46 (3H, s, C(CH₃)₃), 1.43 (6H, s, C(CH₃)₃). **13C NMR** (75 MHz, CDCl₃,

CO₂CH₃), 3.50-3.28 (1H, m, 5-H_B), 3.11 (0.33H, dd, *J* 14.1, 6.5, C*H*_AH_BCH=CH₂), 2.92 (0.67H, dd, *J* 14.1, 6.5, C*H*_AH_BCH=CH₂), 2.61 (1H, dd, *J* 14.1, 8.1, CH_AH_BCH=CH₂), 2.20-1.96 (2H, m, 3-H), 1.96-1.72 (2H, m, 4-H), 1.46 (3H, s, C(CH₃)₃), 1.43 (6H, s, C(CH₃)₃). ¹³C NMR (75 MHz, CDCl₃, mixture of two rotamers): δ 175.4 (major and minor, CO_2CH_3), 154.2 (minor, N(CO)O), 153.8 (major, N(CO)O), 134.0 (minor, CH=CH₂), 133.6 (major, CH=CH₂), 119.3 (major, CH=CH₂), 119.0 (minor, CH=CH₂), 79.8 ($C_q(CH_3)_3$, major and minor), 67.8 (minor, 2-C), 67.2 (major, 2-C), 52.5 (minor, CO₂CH₃), 52.4 (major, CO₂CH₃), 48.8 (minor, 5-C), 48.7 (major, 5-C), 39.9 (major, CH₂CH=CH₂), 38.6 (minor, $CH_2CH=CH_2$), 37.3 (major, 3-C, major), 36.0 (minor, 3-C), 28.7 (minor, C(CH₃)₃), 28.6 (major, C(CH₃)₃), 23.4 (minor, 4-C), 22.9 (major, 4-C). IR v_{max}(film)/cm⁻¹ 2977, 2878, 1742 (CO), 1698 (CO), 1392, 1253, 1162, 1022. HRMS (ESI): C₁₄H₂₃NNaO₄ [M+Na]⁺; calculated 292.1525, found 292.1519. Spectra consistent with the literature values. ^{10,11}

1-tert-Butyl 2-methyl 2-(prop-2-en-1-yl)azetidine-1,2-dicarboxylate 1b


N CO₂Me

General procedure **L** was followed using 1-*tert*-butyl 2-methyl azetidine-1,2-dicarboxylate* (2.4 g, 11 mmol). The residue was washed through a pad of silica with EtOAc to give the *title compound* **1b** (2.26 g, 8.85 mmol, 80%) as a yellow oil. **R**_f 0.07 (91:9 pentane–EtOAc). ¹**H NMR** (500 MHz, CDCl₃, 1:2 mixture of rotamers): δ 5.97-5.84 (1H, m, C*H*=CH₂), 5.23-5.16 (2H, m, CH=CH₂), 4.00-3.86 (1H, m, 4-H_A),

3.77 (3H, s, CO₂CH₃), 3.69 (1H, m, 4-H_B), 2.96-2.86 (0.33H, m, C*H*_AH_BCH=CH₂), 2.76 (0.67H, m, dd, *J* 14.2, 6.0, C*H*_AH_BCH=CH₂), 2.60 (1H, dd, *J* 14.2, 8.1, CH_A*H*_BCH=CH₂), 2.29-2.21 (1H, m, 3-H_A), 2.19-2.11 (1H, m, 3-H_B), 1.40 (9H, s, C(CH₃)₃). ¹³C NMR (125 MHz, CDCl₃): δ 173.1 (CO₂CH₃), 155.1 (N(CO)O), 132.6 (CH=CH₂), 119.6 (CH=CH₂), 80.0 (*C*_q(CH₃)₃), 70.3 (2-C), 52.4 (CO₂CH₃), 44.9 (4-C), 38.8 (C_qCH₂CH=CH₂), 28.4 (C(*C*H₃)₃), 24.3 (3-C). IR v_{max}(film)/cm⁻¹ 2977, 2895, 1739 (CO), 1713 (CO), 1392, 1257, 1157, 1112. HRMS (ESI): C₁₃H₂₂NO₄ [M+H]⁺; calculated 256.1543, found 256.1541.

4-Benzyl 1-tert-butyl 2-methyl 2-(prop-2-en-1-yl)piperazine-

1,2,4-tricarboxylate 1c



General procedure **L** was followed using Boc-protected amino ester **S1c** (3.5 g, 9.2 mmol). The residue was washed through a pad of silica with EtOAc to give the *title compound* **1c** (3.7 g, 8.8 mmol, 96%) was isolated as a yellow oil. ¹**H NMR** (500 MHz, d^6 -DMSO, 340 K): δ 7.41-7.28 (5H, m, Cbz Ar-H), 5.85-5.71 (1H, m, CH=CH₂), 5.17-5.02 (4H, m, CH=CH₂ and OCH₂Ph), 4.01-3.93 (1H, m, NCH_AH_BCH₂N), 3.82-3.77 (1H, m, 3-H_A), 3.66-3.58 (1H, m, 3-H_B), 3.56-3.47 (1H, m, NCH_AH_BCH₂N), 3.43-3.36 (4H, m, includes NCH_AH_BCH₂N and at δ 3.52: 3H, s,

CO₂CH₃), 3.35-3.26 (1H, m, NCH_AH_BCH₂N), 2.92 (1H, d, J 14.5, CH_AH_BCH=CH₂), 2.53-2.44 (1H, m, CH_AH_BCH=CH₂), 1.37 (9H, s, C(CH₃)₃). ¹³C NMR (125 MHz, d⁶-DMSO, 340 K, one carbamate CO peak not observed): δ 172.0 (CO₂CH₃), 153.1 (N(CO)O), 136.5 (Ar-C_q), 132.1 (CH=CH₂), 128.0 (Ar-C), 127.5 (Ar-C), 127.2 (Ar-C), 118.9 (CH=CH₂), 80.0 (C_q(CH₃)₃), 66.0 (CH₂Ph), 63.1 (2-C), 51.6 (CO₂CH₃), 45.3 (3-C), 43.2 (NCH₂CH₂N), 38.3 (NCH₂CH₂N or CH₂CH=CH₂), 37.6 (NCH₂CH₂N or CH₂CH=CH₂), 27.6 (C(CH₃)₃). IR v_{max}(film)/cm⁻¹ 2976, 1746 (CO), 1704 (CO), 1417, 1394, 1366, 1270, 1219. HRMS (ESI): C₂₂H₃₁N₂O₆ [M+H]⁺; calculated 419.2177, found 419.2181.

^{*} Purchased from Fluorochem.

Methyl 2-benzyl-2-[(tert-butoxycarbonyl)amino]pent-4-enoate 1d

1d

To a stirred solution of amino ester **S2d** (322 mg, 1.47 mmol, 1.00 eg.) in THF (10 mL) was added Boc₂O (321 mg, 1.47 mmol, 1.00 eg.) and the reaction mixture was heated at reflux for 15 h. The reaction mixture was concentrated in vacuo, diluted with EtOAc (50 mL), washed with H₂O (50 mL) then brine (50 mL). The organic phase was dried over MgSO₄, filtered, then concentrated in vacuo to give the title compound 1d (470 mg, 1.47 mmol, 99%) as a yellow oil. **R**_f 0.35 (4:1 pentane-EtOAc). ¹**H NMR** (500 MHz,

CDCl₃): δ 7.27-7.19 (3H, m, Ar-H), 7.07-7.04 (2H, m, Ar-H), 5.70-5.59 (1H, m, C*H*=CH₂), 5.33 (1H, br. s, NH), 5.14-5.06 (2H, m, CH=C H_2), 3.75 (3H, s, CO₂CH₃), 3.61 (1H, d, J 13.6, C H_A H_BPh), 3.21 (1H, dd, J 13.7, 7.1, CHAHBCH=CH₂), 3.12 (1H, d, J 13.6, CHAHBPh), 2.59 (1H, dd, J 13.7, 7.4, CH_AH_BCH=CH₂), 1.47 (9H, s, C(CH₃)₃). ¹³C NMR (125 MHz, CDCl₃): δ 173.2 (CO₂CH₃), 154.2 (NH(CO)O), 136.6 $(Ar-C_0)$, 132.6 $(CH=CH_2)$, 130.0 (Ar-C), 128.3 (Ar-C), 127.0 (Ar-C), 119.1 $(CH=CH_2)$, 79.4 $(C_q(CH_3)_3)$, 65.1 (C_q) , 52.6 (CO_2CH_3) , 40.9 (CH_2Ph) , 40.1 $(CH_2CH=CH_2)$, 28.6 (C(CH₃)₃). **IR** v_{max}(film)/cm⁻¹ 3430, 2978, 1739 (CO), 1714 (CO), 1495, 1447, 1348, 1232. **HRMS** (ESI): C₁₈H₂₅NNaO₄ [M+Na]⁺; calculated 342.1681, found 342.1676. Spectra consistent with the literature values. 12

Methyl (3R*,4aR*)-3-(azidomethyl)-1-oxo-hexahydro-1H-pyrrolo[1,2-c][1,3]oxazine-4acarboxylate 5a




General procedure **B** was followed using Boc-carbamate **1a** (200 mg, 0.740 mmol). Flash chromatography eluting with 0-100% EtOAc in pentane gave the title compound **5a** (99 mg, 0.39 mmol, 53%, 95:5 mixture of diastereomers) as a yellow oil. \mathbf{R}_f 0.05 **5a**, dr 95:5 (1:1 petrol–EtOAc). ¹H NMR (500 MHz, CDCl₃): δ 4.30-4.21 (1H, m, 3-H), 3.79 (3H, s, CO₂CH₃), 3.77-3.71 (1H, m, $7-H_A$), 3.67-3.61 (1H, m, $7-H_B$), 3.57 (1H, dd, J13.0, 4.6, $CH_AH_BN_3$), 3.46 (1H, dd, J 13.0, 4.5, HCH_AH_BN₃), 2.63 (1H, dd, J 13.5, 2.6, 4-H_A), 2.55-2.43 (1H, m, 5-H_A), 2.07-1.96 (1H, m, $6-H_A$), 1.90-1.79 (2H, m, 5-H_B and $6-H_B$), 1.74 (1H, dd, J 13.5, 12.3, 4-H_B). ¹³C NMR (125 MHz, CDCl₃): δ 173.5 (CO₂CH₃), 151.5 (1-C), 74.1 (3-C), 67.1 (4a-C), 54.1 (CH₂N₃), 53.6 (CO₂CH₃), 47.4 (7-C), 38.5 (5-C), 33.9 (4-C), 21.7 (6-C). **IR** v_{max}(film)/cm⁻¹ 2955, 2898, 2106 (N₃), 1738 (CO), 1416, 1302, 1210, 1171. **HRMS** (ESI): C₁₀H₁₅N₄O₄ [M+H]⁺; calculated 255.1093, found 255.1088. X-Ray Crystallography: CCDC 1008922 contains the supplementary crystallographic data for this compound. Crystals were grown by slow diffusion of Et₂O into the sample dissolved in the minimum amount of CHCl₃.

Methyl (4R*,6R*)-4-(azidomethyl)-2-oxo-3-oxa-1-azabicyclo[4.2.0]octane-6-carboxylate 5b

Following a procedure by Licini,⁷ NIS (160 mg, 0.710 mmol, 1.20 eq.) was added to a stirred solution of Boc-carbamate **1b** (150 mg, 0.560 mmol, 1.00 eq.) in CHCl₃ (6.0 mL). The reaction mixture was stirred for 4 days and monitored by TLC until complete. The reaction mixture was concentrated *in vacuo*, extracted with EtOAc (25

mL) and washed with sat. aq. $Na_2S_2O_3$ until colourless. The aqueous layer was extracted with EtOAc (2 × 25 mL). The combined organics were dried over Na_2SO_4 , filtered, then concentrated *in vacuo* to give the crude iodide. The iodide was dissolved in DMF (6.0 mL). NaN_3 (114 mg, 1.76 mmol, 3.0 eq.) was added and the reaction mixture was stirred for 48 h. H_2O (25 mL) was added at 0 °C. The reaction mixture was extracted with EtOAc (3 × 25 mL). The combined organic extracts were washed with brine (25 mL), dried over Na_2SO_4 , filtered, then concentrated *in vacuo*. Flash chromatography eluting with 0-100% EtOAc in pentane gave co-elution of the title compound with succinimide. Trituration of the residue with Et₂O gave the *title compound* **5b** (53 mg, 0.22 mmol, 37%) as a colourless solid. **R**_f 0.09 (4:1 pentane–EtOAc). **1H NMR** (500 MHz, CDCl₃): δ 4.44-4.37 (1H, m, 4-H), 4.33-4.25 (1H, m, 8-H_A), 4.15 (1H, td, J 9.6, 4.8, 8-H_B), 3.87 (3H, s, CO_2CH_3), 3.56 (1H, dd, J 13.1, 4.5, $CH_AH_BN_3$), 3.45 (1H, dd, J 13.1, 4.5, $CH_AH_BN_3$), 2.72-2.58 (2H, m, 7-H), 2.48 (1H, dd, J 13.5, 2.2, 5-H_A), 2.02 (1H, dd, J 13.5, 11.9, 5-H_B). ¹³**C NMR** (125 MHz, CDCl₃): δ 172.3 (CO_2CH_3), 154.0 (2-C), 75.9 (4-C), 69.3 (6-C), 53.9 (CH_2N_3), 53.4 (CO_2CH_3), 50.3 (8-C), 33.3 (7-C), 31.6 (5-C). IR V_{max} (film)/cm⁻¹ 2959, 2107 (N_3), 1713 (CO_3), 1392, 1293, 1208, 1155, 762. **HRMS** (ESI): $C_9H_{13}N_4O_4$ [M+H]+; calculated 241.0931, found 241.0930.

2-Benzyl 9a-methyl (8R*,9aS*)-8-(azidomethyl)-6-oxo-octahydropiperazino[1,2-c][1,3]oxazine-2,9a-dicarboxylate 5c




5c, dr 93:7

General procedure **B** was followed using Boc-carbamate **1c** (314 mg, 0.750 mmol). Flash chromatography eluting with 0-100% EtOAc in pentane gave the *title compound* **5c** (195 mg, 0.480 mmol, 64%, 93:7 mixture of diastereomers) as a brown oil. **R**_f 0.04 (4:1 petrol–EtOAc). **1H NMR** (500 MHz, *d*⁶-DMSO, 319 K): δ 7.42-7.29 (5H, m, Cbz Ar-H),

5.12 (1H, d, *J* 12.7, C*H*_AH_BPh), 5.08 (1H, d, *J* 12.7, CH_A*H*_BPh), 4.55 (1H, dd, *J* 13.4, 1.7, 1-H_A), 4.34-4.28 (1H, m, 8-H), 4.13-4.07 (1H, m, NC*H*_AH_BCH₂N), 4.03-3.97 (1H, m, NC*H*_AH_BCH₂N), 3.66 (3H, s, CO₂CH₃), 3.61 (1H, dd, *J* 13.5, 3.2, C*H*_AH_BN₃), 3.44 (1H, dd, *J* 13.5, 5.3, CH_A*H*_BN₃), 3.01 (1H, d, *J* 13.4, 1-H_B), 2.98-2.86 (2H, m, NCH_A*H*_BCH₂N and NCH_A*H*_BCH₂N), 2.26 (1H, dd, *J* 14.0, 2.6, 9-H_A), 2.02 (1H, dd, *J* 14.0, 12.4, 9-H_B). ¹³**C NMR** (125 MHz, *d*⁶-DMSO, 319 K): δ 170.8 (CO₂CH₃), 153.7 (N(CO)O), 151.0 (N(CO)O), 136.4 (Ar-C_q), 128.2 (Ar-C), 127.7 (Ar-C), 127.3

(Ar-C), 71.8 (8-C), 66.4 (CH_2Ph), 61.6 (9a-C), 53.0 (CO_2CH_3), 52.8 (CH_2N_3), 49.9 (1-C), 42.4 (NCH_2CH_2N), 41.0 (NCH_2CH_2N), 30.8 (9-C). **IR** $v_{max}(film)/cm^{-1}$ 2953, 2107 (N_3), 1741 (CO), 1701 (CO), 1432, 1421, 1280, 1230. **HRMS** (ESI): $C_{18}H_{22}N_5O_6$ [M+H]⁺; calculated 404.1565, found 404.1580.

Methyl (4R*,6R*)-6-(azidomethyl)-4-benzyl-2-oxo-1,3-oxazinane-4-carboxylate 5d



General procedure **B** was followed using Boc-carbamate **1d** (100 mg, 0.310 mmol). The residue was washed through a pad of silica with EtOAc–MeOH (9:1) to give the *title compound* **5d** (84 mg, 0.28 mmol, 88%, 87:13 mixture of diastereomers) as a yellow oil. \mathbf{R}_f 0.08 (3:2 petrol–EtOAc). ¹**H NMR** (500 MHz,

CDCl₃, *dr* 87:13, diastereomers were assigned by NOESY, major diastereomer peaks assigned): δ 7.37-7.30 (3H, m, Ar-H), 7.13-7.07 (2H, m, Ar-H), 5.42 (1H, br. s, NH), 4.29-4.22 (1H, m, 6-H), 3.73 (3H, s, CO₂CH₃), 3.55 (1H, dd, *J* 13.2, 4.4, C*H*_AH_BN₃), 3.45 (1H, dd, *J* 13.2, 4.7, CH_A*H*_BN₃), 3.31 (1H, d, *J* 13.4, C*H*_AH_BPh), 2.90 (1H, d, *J* 13.4, CH_AH_BPh), 2.51 (1H, app. dt, *J* 13.9, 2.0, 5-H_A), 1.94 (1H, dd, *J* 13.9, 12.2, 5-H_B). Minor diastereomer characteristic peaks: 5.55 (1H, br. s, NH), 4.43-4.37 (1H, m, 6-H), 3.74 (3H, s, CO₂CH₃), 3.58-3.47 (2H, m, C*H*₂N₃), 3.14 (1H, d, *J* 13.3, C*H*_AH_BPh), 3.04 (1H, d, *J* 13.3, CH_AH_BPh), 2.30 (1H, ddd, *J* 14.3, 2.5, 1.3, 5-H_A), 2.14 (1H, dd, *J* 14.3, 11.6, 5-H_B). ¹³**C NMR** (125 MHz, CDCl₃, peaks of major diastereomer assigned): δ 172.6 (CO₂CH₃), 151.9 (2-C), 133.0 (Ar-C_q), 129.9 (Ar-C), 129.3 (Ar-C), 128.3 (Ar-C), 73.6 (6-C), 61.9 (4-C), 53.7 (CH₂N₃), 53.2 (CO₂CH₃), 46.2 (CH₂Ph), 33.0 (5-C). **IR** v_{max}(film)/cm⁻¹ 3247, 2927, 2105 (N₃), 1713 (CO), 1435, 1403, 1284, 1214. **HRMS** (ESI): C₁₄H₁₆N₄NaO₄ [M+Na]⁺; calculated 327.1064, found 327.1076. The relative configuration of the minor diastereomer was determined by interpretation of the NOESY correlations.

5d, minor diastereomer NOESY correlations:


2-Ethyl 4a-methyl (3R*,4aR*)-3-(azidomethyl)-1-oxo-octahydropyrrolo[1,2-c]pyrimidine-2,4a-dicarboxylate 7a



General procedures **C** and **D** were followed using amino ester **S2a** (1.1 g, 6.7 mmol). Flash chromatography on cyanosilica eluting with a gradient of 0-100% EtOAc in pentane gave the *title compound* **7a** (1.17 g, 3.60 mmol, 54%) as a colourless oil. **R**_f 0.11 (1:1 pentane–EtOAc). ¹**H NMR** (500 MHz, CDCl₃): δ 4.34-4.20 (3H, m, C H_2 CH₃

and 3-H), 3.75-3.67 (5H, includes 2H, m, 7-H and at δ 3.72: 3H, s, CO₂CH₃), 3.65 (1H, dd, *J* 12.3, 5.6, C*H*_AH_BN₃), 3.50 (1H, dd, *J* 12.3, 2.9, CH_AH_BN₃), 2.89 (1H, dd, *J* 13.2, 8.5, 4-H_A), 2.37-2.30 (1H, m, 5-H_A), 2.06-1.92 (3H, m, 5-H_B and 6-H), 1.83 (1H, dd, *J* 13.2, 9.7, 4-H_B), 1.31 (3H, t, *J* 7.1, CH₂C*H*₃). ¹³C NMR (125 MHz, CDCl₃): δ 173.1 (CO₂CH₃), 154.3 (CO), 150.4 (CO), 65.8 (4a-C), 63.1 (O*C*H₂CH₃), 54.5 (CH₂N₃), 53.1 (CO₂*C*H₃), 52.5 (3-C), 46.7 (7-C), 38.1 (5-C), 37.6 (4-C), 22.8 (6-C), 14.5 (OCH₂*C*H₃). IR v_{max}(film)/cm⁻¹ 3597, 3507, 2981, 2106 (N₃), 1708 (CO), 1420, 1296, 1018. HRMS (ESI): C₁₃H₂₀N₅O₅ [M+H]⁺; calculated 326.1459, found 326.1462.


3-Ethyl 6-methyl (4R*,6R*)-4-(azidomethyl)-2-oxo-1,3-diazabicyclo[4.2.0]octane-3,6-dicarboxylate 7b



General procedures **C** and **D** were followed using amino ester **S2b** (150 mg, 0.970 mmol, 1.00 eq.). Flash chromatography eluting with a gradient of 0-100% EtOAc in pentane gave the *title compound* **7b** (98 mg, 0.31 mmol, 32%, 97:3 mixture of diastereomers) as a pale yellow oil. **R**_f 0.17 (1:1 pentane–EtOAc). ¹**H NMR** (500 MHz,

CDCl₃): δ 4.32-4.19 (3H, m, C*H*₂CH₃ and 4-H), 4.16 (1H, td, *J* 9.4, 6.8, 8-H_A), 4.05 (1H, td, *J* 9.4, 5.7, 8-H_B), 3.82-3.76 (4H, m, includes 1H, m, C*H*_AH_BN₃ and at δ 3.80: 3H, s, CO₂CH₃), 3.53 (1H, dd, *J* 12.4, 2.5, CH_A*H*_BN₃), 2.75-2.68 (1H, m, 7-H_A), 2.63 (1H, dd, *J* 13.6, 6.5, 5-H_A), 2.42-2.34 (1H, m, 7-H_B), 2.25 (1H, dd, *J* 13.6, 11.7, 5-H_B), 1.31 (3H, t, *J* 7.1, CH₂C*H*₃). ¹³C NMR (125 MHz, CDCl₃): δ 171.4 (CO₂CH₃), 153.8 (CO), 153.3 (CO), 68.5 (6-C), 63.2 (O*C*H₂CH₃), 55.1 (4-C), 54.0 (*C*H₂N₃), 53.2 (CO₂*C*H₃), 47.2 (8-C), 35.9 (5-C), 28.8 (7-C), 14.4 (OCH₂*C*H₃). IR v_{max}(film)/cm⁻¹ 2978, 2108 (N₃), 1712 (CO), 1390, 1372, 1289, 1245, 1033. HRMS (ESI): C₁₂H₁₈N₅O₅ [M+H]⁺; calculated 312.1303, found 312.1307.

2-Benzyl 7-ethyl 9a-methyl (8R*,9aS*)-8-(azidomethyl)-6-oxo-octahydro-1H-pyrimido[1,6alpiperazine-2,7,9a-tricarboxylate 7c



General procedures C and D were followed using amino ester S2c (150 mg, 0.470 mmol, 1.00 eg.). Flash chromatography eluting with a gradient of 0-100% EtOAc in pentane gave the title compound 7c (98 mg, 0.21 mmol, 44%) as a pale yellow oil. \mathbf{R}_f 0.15 (1:1 pentane-EtOAc). ¹**H NMR** (500 MHz, o^6 -DMSO, 348 K): δ 7.40-7.30 (5H, m, Cbz Ar-H), 5.11 (2H, s, CH₂Ph), 4.33-4.26 (1H, m, 8-H), 4.22 (1H, d, J 13.8, 1-H_A),


4.17 (2H, q, J 7.1, CH₂CH₃), 3.91-3.79 (2H, m, NCH_AH_BCH₂N and NCH_AH_BCH₂N), 3.62-3.57 (4H, m, includes 1H, m, $CH_AH_BN_3$ and at δ 3.59: 3H, s, CO_2CH_3), 3.49 (1H, dd, J 12.7, 5.5, $CH_AH_BN_3$), 3.35 (1H, d, J 13.8, 1-H_B), 3.35 (1H, d, J 13.9, NCH_AH_BCH₂N) 3.33-3.25 (1H, m, NCH_AH_BCH₂N), 2.57 (1H, dd, J 14.1, 8.5, 9-H_A), 1.96 (1H, dd, J 14.1, 6.7, 9-H_B), 1.22 (3H, t, J 7.1, CH₂CH₃). ¹³C NMR (125 MHz, σ -DMSO, 348 K): δ 171.1 (CO₂CH₃), 154.0 (CO), 153.0 (CO), 151.1 (CO), 136.3 (Ar-C_g), 128.0 (Ar-C), 127.5 (Ar-C), 127.1 (Ar-C), 66.2 (CH₂Ph), 61.9 (OCH₂CH₃), 60.9 (9a-C), 53.0 (CH₂N₃), 52.4 (CO₂CH₃), 50.1 (8-C), 48.0 (1-C), 42.4 (NCH₂CH₂N), 38.6 (NCH₂CH₂N), 33.5 (9-C), 13.6 (OCH₂CH₃). **IR** v_{max}(film)/cm⁻¹ 2106 (N₃), 1740 (CO), 1705 (CO), 1416, 1290, 1226, 1145, 769. **HRMS** (ESI): C₂₁H₂₇N₆O₇ [M+H]⁺; calculated 475.1936, found 475.1950.

7a-(Prop-2-en-1-yl)-hexahydro-1H-pyrrolo[1,2-c]imidazolidine-1,3-dione 8a



General procedures C and E were followed using amino ester S2a (200 mg, 1.18 mmol). Purification by SCX, eluting with MeOH, gave the title compound 8a (200 mg, 1.11 mmol, 94%) as a colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 8.14 (1H, br. s, NH), 5.81-5.71 (1H, m, CH=CH₂), 5.22-5.15 (2H, m, CH=CH₂), 3.83-3.75 (1H, m, 5-H_A), 3.21-3.14 (1H, m, 5-H_B), 2.58 (1H, dd, J 14.0, 7.7, CH_AH_BCH=CH₂), 2.41 (1H, dd, J 14.0, 6.8, CH_AH_BCH=CH₂), 2.17-2.03 (2H, m, 6-H), 2.02-1.89 (2H, m, 7-H). ¹³**C NMR** (125 MHz, CDCl₃): δ 176.3 (1-C), 159.5 (3-C), 131.0 (CH=CH₂), 120.6 (CH=CH₂), 73.8 (7a-C), 44.9 (5-C), 39.6 (CH₂CH=CH₂), 32.2 (7-C), 26.3 (6-C). **IR** v_{max}(film)/cm⁻¹ 3210, 3074, 2978, 1771 (CO), 1715 (CO), 1391, 1332, 1208. **HRMS** (EI): C₉H₁₂N₂O₂ [M]⁺; calculated 180.0899, found 180.0897.


Benzyl 1,3-dioxo-8a-(prop-2-en-1-yl)-octahydroimidazolidino[1,5-a]piperazine-7-carboxylate 8c



General procedures **C** and **E** were followed using amino ester **S2c** (141 mg, 0.440 mmol). Purification by SCX, eluting with MeOH, gave the *title compound* **8c** (139 mg, 0.420 mmol, 96%). ¹H **NMR** (500 MHz, σ 6-DMSO, 319 K): δ 10.98 (1H, s, NH), 7.42-7.28 (5H, m, Cbz Ar-H), 5.57-5.44 (1H, m, C*H*=CH₂), 5.18-5.03 (4H, m, CH=C*H*₂ and C*H*₂Ph), 4.02-3.91 (1H, m,

NC*H*_AH_BCH₂N), 3.93 (1H, d, *J* 13.1, 8-H_A), 3.83 (1H, dd, *J* 13.2, 3.0, NC*H*_AH_BCH₂N), 3.19-3.01 (1H, m, 8-H_B), 2.98-2.92 (2H, m, NCH_AH_BCH₂N and NCH_AH_BCH₂N), 2.56 (1H, dd, *J* 14.3, 7.3, C*H*_AH_BCH=CH₂), 2.34 (1H, dd, *J* 14.3, 6.9, CH_AH_BCH=CH₂). ¹³C NMR (125 MHz, *d*⁶-DMSO, 319 K, one C_q peak not observed): δ 174.1 (1-C), 154.4 (CO), 136.4 (Ar-C_q), 130.4 (*C*H=CH₂), 128.2 (Ar-C), 127.8 (Ar-C), 127.5 (Ar-C), 119.7 (CH=*C*H₂), 66.7 (*C*H₂Ph), 62.8 (8a-C), 47.5 (8-C), 42.8 (N*C*H₂CH₂N), 35.8 (N*C*H₂CH₂N), 34.0 (*C*H₂CH=CH₂). IR v_{max}(film)/cm⁻¹ 3199, 1772 (CO), 1708 (CO), 1455, 1428, 1353, 1267, 1244. HRMS (ESI): C₁₇H₂₀N₃O₄ [M+H]⁺; calculated 330.1448, found 330.1449.

5-Benzyl-3-phenyl-5-(prop-2-en-1-yl)imidazolidine-2,4-dione 8d



8d

To a solution of urea **S3d** (47 mg, 0.14 mmol, 1.0 eq.) in PhMe (1.5 mL) was added NaO[†]Bu (14 mg, 0.14 mmol, 1.0 eq.) and the reaction mixture was heated at 100 °C for 15 h. The reaction mixture was cooled to rt then concentrated *in vacuo*. Flash chromatography eluting with 0-100% EtOAc in pentane gave the *title compound* **8d** (36 mg, 0.12 mmol, 85%) as a colourless oil. ¹H **NMR** (500 MHz, CDCl₃):

 δ 7.41-7.36 (2H, m, Ar-H), 7.35-7.29 (4H, m, Ar-H), 7.24-7.18 (2H, m, Ar-H), 6.99-6.94 (2H, m, Ar-H), 6.30 (1H, s, NH), 5.94-5.84 (1H, m, C*H*=CH₂), 5.31-5.21 (2H, m, CH=C*H*₂), 3.21 (1H, d, *J* 13.6, C*H*_AH_BPh), 2.96 (1H, d, *J* 13.6, CH_AH_BPh), 2.75 (1H, dd, *J* 13.9, 7.7, C*H*_AH_BCH=CH₂), 2.56 (1H, dd, *J* 13.9, 7.1, CH_AH_BCH=CH₂). ¹³**C NMR** (125 MHz, CDCl₃): δ 174.2 (4-C), 155.9 (2-C), 134.1 (Ar-C_q), 131.4 (Ar-C_q), 130.4 (2 × C; CH=CH₂ and Ar-C); 129.2 (Ar-C), 128.7 (Ar-C), 128.5 (Ar-C), 127.7 (Ar-C), 126.5 (Ar-C), 121.4 (CH=CH₂), 66.0 (5-C), 42.9 (CH₂Ph), 41.1 (CH₂CH=CH₂). **IR** v_{max}(film)/cm⁻¹ 3290, 1778, 1715 (CO), 1502, 1414, 1123, 919, 703. **HRMS** (ESI): C₁₉H₁₉N₂O₂ [M+H]⁺; calculated 307.1441, found 307.142

8a-(Prop-2-en-1-yl)-octahydropyrrolo[1,2-a]piperazin-1-one 10a

NH NH

10a

General procedures **F** and **G** were followed using amino ester **1a** (400 mg, 2.36 mmol). The residue was purified by SCX, eluting first with MeOH then sat. NH₃/MeOH, to give the *title compound* **10a** (270 mg, 1.50 mmol, 62%) as a brown oil. ¹**H NMR** (500 MHz, CDCl₃): δ 5.95-5.84 (1H, m, C*H*=CH₂), 5.76 (1H, br. s, NH), 5.16-5.07 (2H, m, CH=C*H*₂),

3.72-3.62 (1H, m, 3-H_A), 3.32-3.18 (2H, m, 3-H_B and 4-H_A), 3.09-3.02 (1H, m, 6-H_A), 2.96-2.82 (2H, m, 4-H_B and 6-H_B), 2.62 (1H, dd, *J* 13.9, 6.6, C*H*_AH_BCH=CH₂), 2.43 (1H, dd, *J* 13.9, 7.9, CH_AH_BCH=CH₂), 2.20-2.12 (1H, m, 8-H_A), 2.01-1.93 (1H, m, 8-H_B), 1.83-1.69 (2H, m, 7-H). ¹³**C NMR** (125 MHz, CDCl₃): δ 176.3 (1-C), 134.4 (*C*H=CH₂), 117.8 (CH=*C*H₂), 68.4 (8a-C), 51.9 (6-C), 43.4 (4-C), 42.6 (*C*H₂CH=CH₂), 38.5 (3-C), 34.9 (8-C), 22.8 (7-C). **IR** v_{max}(film)/cm⁻¹ 3218, 3074, 2944, 1655 (CO), 1487, 1447, 915, 753. **HRMS** (ESI): C₁₀H₁₇N₂O [M+H]⁺; calculated 181.1341, found 181.1335.


6-(Prop-2-en-1-yl)-1,4-diazabicyclo[4.2.0]octan-5-one 10b



General procedures **F** and **G** were followed using the TFA salt of the amino ester **S2b** (404 mg, 1.50 mmol). Flash chromatography on eluting with a gradient of 0-100% EtOAc in pentane containing 1% Et₃N gave the *title compound* **10b** (54 mg, 0.32 mmol, 22%) as a pale yellow oil. **R**_f 0.19 (1:1 petrol–EtOAc). ¹H **NMR** (500 MHz, CDCl₃): δ 6.97 (1H, br. s,

NH), 5.83-5.72 (1H, m, C*H*=CH₂), 5.29-5.19 (2H, m, CH=C*H*₂), 4.39-4.32 (1H, m, 8-H_A), 4.28-4.20 (1H, m, 8-H_B), 3.47-3.34 (2H, m, 3-H), 2.94-2.86 (1H, m, 2-H_A), 2.77-2.70 (1H, m, 2-H_B), 2.52 (1H, dd, *J* 14.0, 7.2, C*H*_AH_BCH=CH₂), 2.38 (1H, dd, *J* 14.0, 7.5, CH_AH_BCH=CH₂), 2.29-2.19 (2H, m, 7-H). ¹³**C NMR** (125 MHz, CDCl₃): δ 178.4 (5-C), 131.1 (*C*H=CH₂), 121.0 (CH=*C*H₂), 65.0 (8-C), 61.8 (6-C), 41.6 (2-C), 40.1 (2 × C; 3-C and *C*H₂CH=CH₂), 32.1 (7-C). **IR** v_{max}(film)/cm⁻¹ 3325 (NH), 2982, 1763 (CO), 1719, 1560, 1183, 1024, 927. **HRMS** (EI): C₉H₁₄N₂O [M]⁺; calculated 166.1106, found 166.1133.

3-Benzyl-3-(prop-2-en-1-yl)piperazine-2,5-dione 11d




General procedure $\bf G$ was followed using amide $\bf S4d$ (50 mg, 0.13 mmol, 1.0 eq.). Flash chromatography eluting with a gradient of 0-10% MeOH in CH_2Cl_2 gave the

title compound **11d** (30 mg, 0.12 mmol, 93%) as a colourless solid. **R**_f 0.33 (5:95 CH₂Cl₂–MeOH). **1H NMR** (500 MHz, CD₃OD, 2 × NH not observed): δ 7.34-7.30

(3H, m, Ar-H), 7.27-7.22 (2H, m, Ar-H), 5.85-5.75 (1H, m, C*H*=CH₂), 5.28-5.18 (2H, m, CH=C*H*₂), 3.46 (1H, d, *J* 17.9, 6-H_A), 3.27 (1H, d, *J* 13.3, C*H*_AH_BPh), 2.95 (1H, dd, *J* 13.8, 6.6, C*H*_AH_BCH=CH₂), 2.80 (1H, d, *J* 13.3, CH_A*H*_BPh), 2.62 (1H, d, *J* 17.9, 6-H_B), 2.43 (1H, dd, *J* 13.8, 7.8, CH_A*H*_BCH=CH₂).

¹³C NMR (125 MHz, CD₃OD): δ 170.8 (CO), 168.8 (CO), 136.5 (CH=CH₂), 133.1 (Ar-C_q), 131.8 (Ar-C), 129.4 (Ar-C), 128.4 (Ar-C), 120.4 (CH=CH₂), 65.4 (3-C), 47.4 (6-C), 44.9 (CH₂Ph), 44.6 (CH₂CH=CH₂). IR v_{max} (film)/cm⁻¹ 3192, 3071, 2917, 2332, 1673 (CO), 1451, 1316, 1108. HRMS (ESI): C₁₄H₁₆N₂NaO₂ [M+Na]⁺; calculated 267.1104, found 267.1092.


Methyl 1-[(2-bromophenyl)methyl]-2-(prop-2-en-1-yl)pyrrolidine-2-carboxylate 12a



General procedure **H** was followed using amino ester **S2a** (250 mg, 1.48 mmol). The residue was purified by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, to give the *title compound* (392 mg, 1.16 mmol, 78%) as a colourless oil. **R**_f 0.26 (4:1 pentane–EtOAc). ¹**H NMR** (300 MHz, CDCl₃): δ 7.52 (1H, dd, J 7.9, 1.1, Ar-H), 7.47 (1H, dd, J 7.6, 1.1, Ar-H), 7.31-7.23 (1H, m, Ar-H), 7.09 (1H, td,

J7.6, 1.6, Ar-H), 5.96-5.78 (1H, CH=CH₂), 5.14-5.06 (2H, CH=CH₂), 3.98 (1H, d, J15.0, CH_AH_BAr), 3.76 (3H, s, CO₂CH₃), 3.67 (1H, d, J15.0, CH_AH_BAr), 2.97 (1H, td, J8.5, 3.5, 5-H_A), 2.77-2.58 (2H, m, 5-H_B and CH_AH_BCH=CH₂), 2.46 (1H, dd, J14.1, 6.6, CH_AH_BCH=CH₂), 2.24-2.16 (1H, m, 3-H_A), 1.95-1.82 (2H, m, 3-H_B and 4-H_A), 1.81-1.72 (1H, m, 4-H_B). ¹³**C NMR** (125 MHz, CDCl₃): δ 174.9 (CO₂CH₃), 139.1 (Ar-C_q), 134.4 (CH=CH₂), 132.7 (Ar-C), 130.2 (Ar-C), 128.2 (Ar-C), 127.3 (Ar-C), 124.0 (Ar-C_q-Br), 118.1 (CH=CH₂), 70.7 (2-C), 53.2 (CH₂Ar), 51.9 (5-C), 51.4 (CO₂CH₃), 39.7 (CH₂CH=CH₂), 34.0 (3-C), 22.0 (4-C). **IR** V_{max}(film)/cm⁻¹ 2949, 1727 (CO), 1439, 1219, 1193, 1171, 1025, 916. **HRMS** (ESI): C₁₆H₂₁⁷⁹BrNO₂ [M+H]+; calculated 338.0756, found 338.0750.

Methyl 1-[(2-bromophenyl)methyl]-2-(prop-2-en-1-yl)azetidine-2-carboxylate 12b




Method 1: General procedure **H** was followed using amino ester **S2b** (175 mg, 1.13 mmol). The residue was purified by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, to give the *title compound* **12b** (246 mg, 0.759 mmol, 67%) as a colourless oil. **Method 2:** To a stirred solution of the TFA salt of the amino ester **S2b** (404 mg, 1.50 mmol, 1.00 eq.) in DMF (7.5 mL) was added 2-bromobenzyl bromide

(0.01 M in THF, 0.45 mL, 0.45 mmol, 3.00 eq.) and K_2CO_3 (456 mg, 3.30 mmol, 2.20 eq.) and the reaction mixture was heated at 60 °C for 15 h. The reaction mixture was diluted with H_2O (20 mL) and extracted with EtOAc (2 × 20 mL). The combined organics were washed with brine (20 mL) then dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, gave the *title compound* **12b** (358 mg, 1.10 mmol, 74%) as a colourless oil. ¹H NMR (500 MHz, CDCl₃): δ 7.51 (1H, dd, J 8.0, 1.2, Ar-H), 7.43 (1H, dd, J 7.7, 1.2, Ar-H), 7.28-7.24 (1H, m, Ar-H), 7.08 (1H, td, J 7.7, 1.7, Ar-H), 5.84-5.74 (1H, m, CH=CH₂), 5.17-5.07 (2H, m, CH=CH₂), 3.86-3.76 (5H, m includes 2H, dd, J 14.3, CH₂Ar and at δ 3.77: 3H, s, CO₂CH₃),

3.31-3.25 (1H, m, 4-H_A), 3.25-3.19 (1H, m, 4-H_B), 2.71 (1H, dd, J 13.7, 7.3, $CH_{A}H_{B}CH=CH_{2}$), 2.65 (1H, dd, J 13.7, 6.9, $CH_{A}H_{B}CH=CH_{2}$), 2.58-2.51 (1H, m, 3-H_A), 2.15-2.07 (1H, m, 3-H_B). ¹³**C NMR** (125 MHz, CDCl₃): δ 173.7 ($CO_{2}CH_{3}$), 138.0 (Ar-C_q), 132.9 (Ar-C or $CH=CH_{2}$), 132.8 (Ar-C or $CH=CH_{2}$), 130.3 (Ar-C), 128.4 (Ar-C), 127.4 (Ar-C), 124.2 (Ar-C_q-Br), 118.6 ($CH=CH_{2}$), 72.0 (2-C), 55.6 ($CH_{2}Ar$), 51.7 ($CO_{2}CH_{3}$), 50.3 (4-C), 38.9 ($CH_{2}CH=CH_{2}$), 25.9 (3-C). **IR** $V_{max}(film)/cm^{-1}$ 2950, 2843, 1728 (CO), 1440, 1214, 1146, 1025, 751. **HRMS** (ESI): $C_{15}H_{19}^{79}BrNO_{2}$ [M+H]+; calculated 324.0594, found 324.0598.


1-Benzyl 3-methyl 4-[(2-bromophenyl)methyl]-3-(prop-2-en-1-yl)piperazine-1,3-dicarboxylate 12c



To a stirred solution amino ester **S2c** (225 mg, 0.71 mmol, 1.00 eq.) in DMF (3.6 mL) was added 2-bromobenzyl bromide (10.4 M in THF, 200 μ L, 2.13 mmol, 3.00 eq.) and K₂CO₃ (108 mg, 0.780 mmol, 1.10 eq.). The reaction mixture was heated at 60 °C for 24 h, then diluted with H₂O (20 mL) and extracted with EtOAc (2 × 20 mL). The combined organics were washed with brine (20 mL) then dried over MgSO₄, filtered, and concentrated *in vacuo*. Purification by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, gave the *title compound* **12c** (288

mg, 0.591 mmol, 83%) as an orange oil. ¹H NMR (500 MHz, σ 6-DMSO, 319 K): δ 7.61 (1H, d, J7.0, Ar-H), 7.57 (1H, dd, J 7.9, 0.9, Ar-H), 7.42-7.29 (6H, m, Ar-H), 7.19 (1H, td, J 7.9, 1.5, Ar-H), 5.82-5.71 (1H, m, CH=CH₂), 5.14-5.01 (4H, m, CH=CH₂ and OCH₂Ph), 4.27 (1H, d, J 13.4, 2-Ha), 4.12 (1H, d, J 16.6, NCHaHBAr), 3.84 (1H, d, J 12.9, NCHaHBCH₂N), 3.79 (1H, d, J 16.6, NCHaHBAr), 3.59 (3H, s, CO₂CH₃), 3.09 (1H, d, J 13.4, 2-HB), 3.05-2.95 (1H, m, NCHaHBCH₂N), 2.71 (1H, td, J 11.8, 3.5, NCHaHBCH₂N), 2.65-2.53 (2H, m, CH₂CH=CH₂), 2.53-2.46 (1H, m, NCHaHBCH₂N). ¹³C NMR (125 MHz, σ 6-DMSO, 319 K): δ 172.5 (CO₂CH₃), 154.0 (N(CO)O), 138.1 (Ar-C_q), 136.8 (Ar-C_q), 132.3 (Ar-C or CH=CH₂), 132.2 (Ar-C or CH=CH₂), 129.2 (Ar-C), 128.3 (Ar-C), 128.2 (Ar-C), 127.6 (Ar-C), 127.5 (Ar-C), 127.2 (Ar-C), 122.9 (Ar-C_q-Br), 118.7 (CH=CH₂), 66.0 (OCH₂Ph), 64.5 (3-C), 53.3 (NCH₂Ar), 51.2 (CO₂CH₃), 49.6 (2-C), 46.6 (NCH₂CH₂N), 43.2 (NCH₂CH₂N), 38.0 (CH₂CH=CH₂). IR v_{max}(film)/cm⁻¹ 2950, 1732 (CO), 1704, 1456, 1435, 1284, 1228, 1212. HRMS (ESI): C₂4H₂8⁷⁹BrN₂O₄ [M+H]+; calculated 487.1227, found 487.1233.


Methyl 2-benzyl-2-[(2-bromobenzyl)amino]pent-4-enoate 12d



General procedure **H** was followed using amino ester **S2d** (268 mg, 1.22 mmol) with two changes; the reaction was performed in THF at 45 °C. After heating for 3 days, additional NaBH(OAc)₃ (518 mg, 2.44 mmol, 2.0 eq.) was added and the reaction mixture was stirred for 3 h. Flash chromatography eluting with a gradient of 0-20% EtOAc in hexane gave the *title compound* **12d** (327 mg, 0.842 mmol, 69%) as a colourless oil. **R**_f 0.68 (4:1 petrol–EtOAc). ¹**H NMR** (500 MHz, CDCl₃): δ 7.53 (1H, dd,

J 8.0, 1.2, Ar-H), 7.47 (1H, d, J 7.5, Ar-H), 7.26 (4H, m, Ar-H), 7.16 (2H, d, J 6.9, Ar-H), 7.11 (1H, td, J 7.7, 1.6, Ar-H), 6.00-5.88 (1H, m, CH=CH2), 5.23-5.13 (2H, m, CH=CH2), 3.89-3.79 (2H, m, NHCH2Ar), 3.67 (3H, s, CO2CH3), 3.09 (1H, d, J 13.7, CH3HBPh), 3.01 (1H, d, J 13.7, CH3HBPh), 2.65 (1H, dd, J 14.8, 6.1, CH3HBCH=CH2), 2.52 (1H, dd, J 14.8, 7.6, CH3HBCH=CH2). ¹³**C NMR** (125 MHz, CDCI3, one Ar-C peak not observed): δ 175.3 (CO2CH3), 139.5 (Ar-Cq), 136.4 (Ar-Cq), 133.3 (Ar-C), 132.8 (CH=CH2), 130.3 (Ar-C), 128.7 (Ar-C), 128.3 (Ar-C), 127.7 (Ar-C), 127.0 (Ar-C), 124.0 (Ar-Cq-Br), 118.8 (CH=CH2), 66.2 (Cq), 51.8 (CO2CH3), 47.3 (CO4CH3), 1197, 1206, 750. **HRMS** (CO4CH=CO4CH2). **IR** V6Max(film)/cm⁻¹ 2949, 1732 (CO5), 1465, 1439, 1213, 1197, 1206, 750. **HRMS** (CO5): C50H23⁷⁹BrNO2 [CO6H+CO7+ calculated 388.0907, found 388.0913.

Methyl 9-methylidene-3-azatricyclo[$8.4.0.0^{3,7}$]tetradeca-1(10),11,13-triene-7-carboxylate 13a and methyl (9Z)-3-azatricyclo[$9.4.0.0^{3,7}$]pentadeca-1(11),9,12,14-tetraene-7-carboxylate 14a



92:8 mixture **13a:14a**

General procedure I was followed using amino ester **12a** (105 mg, 0.310 mmol, 1.0 eq.). Flash chromatography eluting with pentane–EtOAc (4:1) gave the *title compound* (43 mg, 0.17 mmol, 54%, 92:8 mixture of **13a**:**14b**) as a yellow oil. \mathbf{R}_f 0.21 (4:1 petrol–EtOAc). ¹H NMR (500 MHz, CDCl₃, peaks for **13a**): δ 7.37-7.30 (1H, m, Ar-H), 7.25-7.18 (2H, m, Ar-H),

7.17-7.11 (1H, m, Ar-H), 5.33 (1H, d, J1.6, C=CH_AH_B), 5.12 (1H, s, C=CH_AH_B), 4.54 (1H, d, J16.0, 2-H_A), 3.89 (1H, d, J16.0, 2-H_B), 3.73 (3H, s, CO₂CH₃), 3.13 (1H, d, J13.6, 8-H_A), 3.05 (1H, td, J8.4, 2.4, 4-H_A), 2.76 (1H, app. q, J8.4, 4-H_B), 2.58 (1H, d, J13.6, 8-H_B), 2.26-2.16 (1H, m, 6-H_A), 2.10-2.00 (1H, m, 6-H_B), 1.95-1.83 (1H, m, 5-H_A), 1.81-1.69 (1H, m, 5-H_B). Characteristic peaks for **14a**: 6.79 (1H, d, J10.6, 10-H), 5.94-5.87 (1H, m, 9-H), 4.09 (1H, d, J14.8, 2-H_A), 4.02 (1H, d, J14.8, 2-H_B), 3.77 (3H, s, CO₂CH₃), 2.74-2.67 (1H, m), 2.46 (1H, dd, J13.4, 7.5, 8-H_A), 2.37-2.30 (1H, m). ¹³**C NMR** (125 MHz, CDCl₃, peaks for **13a** assigned): δ 175.7 (CO₂CH₃), 145.5 (9-C), 141.3 (Ar-C_q), 136.8 (Ar-C_q), 129.3 (Ar-C), 127.5 (Ar-C), 127.4 (Ar-C), 127.2 (Ar-C), 116.9 (C=CH₂), 69.9 (7-C), 52.9 (2-C), 52.0 (CO₂CH₃), 50.7 (4-C), 41.8 (8-C), 36.1 (6-C), 22.3 (5-C). **IR** V_{max}(film)/cm⁻¹

2949, 2902, 1727 (CO), 1433, 1256, 1209, 1157, 1111. **HRMS** (EI): C₁₆H₁₉N₂O [M]⁺; calculated 257.1409. found 257.1416.


Methyl 8-methylidene-3-azatricyclo[7.4.0.0^{3,6}]trideca-1(9),10,12-triene-6-carboxylate 13b

CO₂Me

General procedure **I** was followed using amino ester **12b** (163 mg, 0.500 mmol). After heating at 125 °C under microwave irradiation for 2 h, additional Pd(PPh₃)₄ (29 mg, 25 μ mol, 5.0 mol%) was added and the reaction mixture heated for a further 2 h. Flash chromatography eluting with a gradient of 0-100% EtOAc in pentane (containing 1% Et₃N) gave the *title compound* **13b** (35 mg, 0.14 mmol, 29%) as a yellow oil.

R_f 0.07 (4:1 petrol–EtOAc). ¹**H NMR** (500 MHz, CDCl₃): δ 7.49-7.43 (1H, m, Ar-H), 7.30-7.18 (2H, m, Ar-H), 7.15-7.10 (1H, m, Ar-H), 5.50 (1H, s, C=C*H*_AH_B), 5.23 (1H, d, *J* 1.0, C=CH_AH_B), 4.22 (1H, d, *J* 15.2, 2-H_A), 3.89 (1H, d, *J* 15.2, 2-H_B), 3.60 (3H, s, CO₂CH₃), 3.35-3.28 (1H, m, 4-H_A), 3.25-3.15 (2H, m, 4-H_B and 7-H_A), 3.06 (1H, d, *J* 15.1, 7-H_B), 2.65-2.55 (1H, m, 5-H_A), 2.29-2.26 (1H, m, 5-H_B). ¹³**C NMR** (125 MHz, CDCl₃): δ 175.5 (*C*O₂CH₃), 144.7 (8-C), 139.8 (Ar-C_q), 135.8 (Ar-C_q), 129.8 (Ar-C), 128.2 (Ar-C), 127.8 (Ar-C), 127.6 (Ar-C), 117.2 (C=*C*H₂), 69.2 (6-C), 54.9 (2-C), 52.2 (CO₂CH₃), 46.6 (4-C), 39.6 (7-C), 26.7 (5-C). **IR** v_{max}(film)/cm⁻¹ 2921, 1736 (CO), 1484, 1435, 1257, 1235, 1104, 775. **HRMS** (ESI): C₁₅H₁₈NO₂ [M+H]⁺; calculated 244.1332, found 244.1335.

13-Benzyl 11-methyl 9-methylidene-1,13-diazatricyclo[9.4.0.0^{3,8}]pentadeca-3(8),4,6-triene-11,13-dicarboxylate 13c and 14-benzyl 12-methyl (9*Z*)-1,14-dicarboxylate 14c diazatricyclo[10.4.0.0^{3,8}]hexadeca-3(8),4,6,9-tetraene-12,14-dicarboxylate 14c




General procedure I was followed using amino ester 12c (280 mg, 0.570 mmol, 1.00 eq.). Flash chromatography eluting with a gradient of 0-100% EtOAc in pentane gave the separable *title compounds* 13c (74 mg, 0.18 mmol, 32%) and 14c (72 mg, 0.18 mmol, 31%) as pale yellow oils.*

13-Benzyl 11-methyl 9-methylidene-1,13-diazatricyclo[9.4.0.0^{3,8}]**pentadeca-3(8),4,6-triene-11,13-dicarboxylate 13c**: **R**_f 0.11 (4:1 petrol–EtOAc). ¹**H NMR** (500 MHz, *σ*⁶-DMSO, 319 K): δ 7.42-7.29 (6H, m, Ar-H), 7.21-7.14 (2H, m, Ar-H), 7.13-7.08 (1H, m, Ar-H), 5.40 (1H, s, C=C*H*_AH_B), 5.12 (1H, s, C=CH_AH_B), 5.12-5.03 (2H, m, OC*H*₂Ph), 4.49 (1H, d, *J* 17.0, 2-H_A), 4.22 (1H, d, *J* 12.8, 12-H_A), 3.79 (1H, d, *J* 12.8, NC*H*_AH_BCH₂N), 3.64 (1H, d, *J* 17.0, 2-H_B), 3.58 (3H, s, CO₂CH₃),

Analysis of the crude product by 500 MHz NMR spectroscopy showed 100% conversion to a 42:58 mixture of 13c:14c.

3.28-3.18 (1H, m, $NCH_AH_BCH_2N$), 3.15 (1H, d, J 12.8, 12-H_B), 2.90 (1H, br. s, $NCH_AH_BCH_2N$), 2.78 (1H, d, J 13.8, 10-H_A), 2.69 (1H, d, J 11.4, NCH_AH_BCH₂N), 2.63 (1H, d, J 13.8, 10-H_B). ¹³C NMR (125 MHz, σ^6 -DMSO, 319 K): δ 172.7 (CO_2CH_3), 154.2 (N(CO)O), 143.9 (9-C), 139.4 (Ar-C₀), 139.1 (Ar- C_0), 136.7 (Ar- C_0), 128.2 (Ar-C), 127.6 (Ar-C), 127.5 (Ar-C), 127.3 (Ar-C), 127.0 (Ar-C), 126.8 (Ar-C), 126.2 (Ar-C), 115.9 (C= CH_2), 66.1 (O CH_2 Ph), 64.8 (11-C), 56.6 (2-C), 51.2 (CO₂ CH_3), 49.0 (12-C), 48.8 (NCH₂CH₂N), 43.4 (NCH₂CH₂N), 41.2 (10-C). **IR** v_{max}(film)/cm⁻¹ 2946, 1732 (CO), 1702, 1461, 1432, 1277, 1223, 1128. **HRMS** (ESI): C₂₄H₂₇N₂O₄ [M+H]⁺; calculated 407.1965, found (9Z)-1,14-diazatricyclo[10.4.0.0^{3,8}]hexadeca-3(8),4,6,9-407.1975. 14-Benzyl 12-methyl tetraene-12,14-dicarboxylate 14c: R_f 0.21 (4:1 petrol-EtOAc). ¹H NMR (500 MHz, σ^6 -DMSO, 319 K): δ 7.45 (1H, d, J 7.0, Ar-H), 7.40-7.30 (5H, m, Ar-H), 7.29-7.22 (2H, m, Ar-H), 7.16 (1H, d, J7.1, Ar-H), 6.78 (1H, d, J10.7, 9-H), 5.78 (1H, app. q, J9.1, 10-H), 5.13-5.00 (2H, m, OC H_2 Ph), 4.23 (1H, d, J 13.0, 13-H_A), 3.93-3.81 (2H, m, NCH_AH_BCH₂N and 2-H_A), 3.65-3.51 (4H, m, includes 1H, m, 2-H_B and at δ 3.57: 3H, s, CO₂CH₃), 3.42 (1H, td, J 11.5, 3.3, NCH_AH_BCH₂N), 3.06-2.90 (2H, m, $NCH_AH_BCH_2N$ and $NCH_AH_BCH_2N$), 2.73 (1H, d, J13.0, 13-H_B), 2.40 (1H, dd, J13.2, 7.6, 11-H_A), 1.66 (1H, dd, J 13.2, 9.3, 11-H_B). ¹³C NMR (125 MHz, σ ⁶-DMSO, 319 K): δ 171.6 (CO_2CH_3), 153.8 (N(CO)O), 138.7 (Ar-C_q), 136.6 (Ar-C_q), 135.3 (Ar-C_q), 132.5 (9-C), 130.9 (Ar-C), 128.2 (2 × Ar-C), 127.6 (Ar-C), 127.2 (3 peaks, $3 \times C$; 10-C and $2 \times Ar-C$), 126.5 (Ar-C), 66.1 (OCH₂Ph), 60.4 (12-C), 55.8 (2-C), 52.4 (13-C), 51.1 (NCH₂CH₂N and CO₂CH₃), 44.0 (NCH₂CH₂N), 35.3 (11-C). IR v_{max}(film)/cm⁻¹ 3010, 2948, 1733 (CO), 1701, 1456, 1432, 1284, 1232. HRMS (ESI): C₂₄H₂₇N₂O₄ [M+H]+; calculated 407.1965, found 407.1980.

Methyl 3-benzyl-5-methylidene-2,3,4,5-tetrahydro-1H-2-benzazepine-3-carboxylate 13d



Et₃N (90 μL, 0.65 mmol, 2.5 eq.) was added to a stirred solution of amino ester **12d** (100 mg, 0.260 mmol, 1.00 eq.), Pd(OAc)₂ (3.0 mg, 13 μmol, 5.0 mol%) and PPh₃ (7.0 mg, 27 μmol, 10 mol%) in MeCN (4 mL). The reaction mixture was heated at 125 °C under microwave irradiation for 1 h. Additional Pd(OAc)₂ (3.0 mg, 13 μmol, 5.0 mol%) and PPh₃ (7.0 mg, 27 μmol, 10 mol%) was added and the reaction mixture

heated for 1 h. The reaction mixture was filtered through Celite then concentrated *in vacuo*. Flash chromatography eluting with 80:20:1 pentane–EtOAc–Et₃N gave the *title compound* **13d** (72 mg, 0.23 mmol, 90%) as a colourless oil. \mathbf{R}_f 0.29 (4:1 petrol–EtOAc). ¹H NMR (500 MHz, CDCl₃): δ 7.38-7.29 (1H, m, Ar-H), 7.24-7.14 (4H, m, Ar-H), 7.13-7.04 (4H, m, Ar-H), 7.00-6.95 (1H, m, NH), 5.37 (1H, s, C=C H_AH_B), 5.06 (1H, s, C=C H_AH_B), 3.97-3.87 (2H, m, 1-H), 3.59 (3H, s, CO₂CH₃), 3.02-2.97 (3H, m, 4-H and C H_AH_B Ph), 2.72 (1H, d, J 13.5, CH_A H_B Ph). ¹³C NMR (125 MHz, CDCl₃): δ 175.4 (CO_2CH_3), 144.8 (5-C), 140.3 (Ar-C_q), 139.8 (Ar-C_q), 136.3 (Ar-C_q), 130.1 (Ar-C),

128.4 (Ar-C), 128.1 (Ar-C), 128.0 (Ar-C), 127.5 (Ar-C), 127.1 (Ar-C), 126.9 (Ar-C), 116.0 (C= CH_2), 67.5 (3-C), 51.9 (CO₂ CH_3), 48.8 (1-C), 44.3 (4-C or CH_2 Ph), 43.8 (4-C or CH_2 Ph). **IR** v_{max} (film)/cm⁻¹ 2949, 1733 (CO), 1454, 1435, 1196, 909, 735, 701. **HRMS** (ESI): $C_{20}H_{22}NO_2$ [M+H]⁺; calculated 308.1645, found 308.1635.

Methyl 1,2-bis(prop-2-en-1-yl)pyrrolidine-2-carboxylate 15a

General procedure **J** was followed using amino ester **S2a** (1.0 g, 5.9 mmol). Purification by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, gave the *title compound* **15a** (1.0 g, 4.8 mmol, 81%) as an orange oil. **R**_f 0.27 (1:1 pentane–EtOAc). ¹**H NMR** (300 MHz, CDCl₃): δ 5.92–5.67 (2H, m, C_qCH₂C*H*=CH₂ and NCH₂C*H*=CH₂), 5.22-4.96 (4H, m, C_qCH₂CH=C*H*₂ and NCH₂CH=C*H*₂), 3.67 (3H, s, CO₂CH₃), 3.38 (1H, dd, *J* 13.7, 5.0,


(4H, m, $C_qCH_2CH=CH_2$ and $NCH_2CH=CH_2$), 3.67 (3H, s, CO_2CH_3), 3.38 (1H, dd, J 13.7, 5.0, $NCH_AH_BCH=CH_2$), 3.15-2.97 (1H, m, 5-H_A), 2.84 (1H, dd, J 13.7, 7.5, $NCH_AH_BCH=CH_2$), 2.69-2.48 (2H, m, 5-H_B and $C_qCH_AH_BCH=CH_2$), 2.31 (1H, dd, J 14.0, 6.8, $C_qCH_AH_BCH=CH_2$), 2.19-1.99 (1H, m, 3-H_A), 1.92-1.65 (3H, m, 3-H_B and 4-H). ¹³**C NMR** (75 MHz, $CDCI_3$): δ 174.6 (CO_2CH_3), 136.9 ($NCH_2CH=CH_2$ or $C_qCH_2CH=CH_2$), 134.3 ($NCH_2CH=CH_2$ or $C_qCH_2CH=CH_2$), 118.0 ($NCH_2CH=CH_2$ or $C_qCH_2CH=CH_2$), 70.2 (2-C), 52.5 ($NCH_2CH=CH_2$), 51.8 (5-C), 51.2 (CO_2CH_3), 39.4 ($C_qCH_2CH=CH_2$), 33.9 (3-C), 21.6 (4-C). **IR** V_{max} (film)/cm⁻¹ 3077, 2978, 2951, 2814, 1738 (CO), 1642, 1445, 1434. **HRMS** (ESI): $C_{12}H_{20}NO_2$ [M+H]+; calculated 210.1494, found 210.1489.

Methyl 1,2-bis(prop-2-en-1-yl)azetidine-2-carboxylate 15b

General procedure **J** was followed using the TFA salt of the amino ester **S2b** (404 mg, 1.50 mmol, 1.0 eq.) and K₂CO₃ (2.2 eq.). Purification by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, gave the *title compound* **15b** (183 mg, 0.937 mmol, 62%) as an orange oil. ¹**H NMR** (500 MHz, CDCl₃): δ 5.81-5.65 (2H, m, NCH₂C*H*=CH₂ and C_qCH₂C*H*=CH₂), 5.19-5.02 (4H, m, NCH₂CH=C*H*₂ and C_qCH₂CH=C*H*₂), 3.74 (3H, s,

CO₂CH₃), 3.25-3.18 (1H, m, 4-H_A), 3.18-3.12 (3H, m, 4-H_B and NC H_2 CH=CH₂), 2.66 (1H, dd, J 13.6, 7.3, C_qC H_A H_BCH=CH₂), 2.55 (1H, m, C_qCH_A H_B CH=CH₂), 2.52-2.47 (1H, m, 3-H_A), 2.08-2.00 (1H, m, 3-H_B). ¹³C NMR (125 MHz, CDCl₃): δ 173.7 (CO₂CH₃), 134.9 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 132.8 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 118.5 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 117.1 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 71.5 (2-C), 54.9 (NCH₂CH=CH₂), 51.6 (CO₂CH₃), 49.4 (4-C), 38.7 (C_qCH₂CH=CH₂), 25.8 (3-C). IR v_{max}(film)/cm⁻¹ 2952, 2848, 1728 (CO), 1640 (CO), 1435, 1259, 1200, 1146. HRMS (ESI): C₁₁H₁₈NO₂ [M+H]⁺; calculated 196.1338, found 196.1328.


1-Benzyl 3-methyl 3,4-bis(prop-2-en-1-yl)piperazine-1,3-dicarboxylate 15c



General procedure **J** was followed using amino ester **S2c** (230 mg, 0.720 mmol). Purification by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, gave the *title compound* **15c** (212 mg, 0.591 mmol, 82%) as an orange oil. ¹**H NMR** (500 MHz, σ -DMSO, 319 K): σ 7.42-7.27 (5H, m, Cbz Ar-H), 5.86-5.66 (2H, m, NCH₂CH=CH₂ and C_qCH₂CH=CH₂), 5.22-5.01 (6H, m, CH₂Ph, NCH₂CH=CH₂ and C_qCH₂CH=CH₂), 4.15 (1H, dd, σ 13.3, 1.5, 2-H_A), 3.85 (1H, d, σ 13.0, NCH_AH_BCH₂N), 3.62-3.56 (1H, m, NCH_AH_BCH=CH₂), 3.54 (3H, s, CO₂CH₃),

3.00-2.85 (3H, m, 2-H_B, NCH_A H_B CH=CH₂ and NCH_A H_B CH₂N), 2.72-2.54 (3H, m, NC H_2 CH₂N, and C_qC H_A H_BCH=CH₂), 2.50 (1H, m, C_qCH_A H_B CH=CH₂). ¹³**C NMR** (125 MHz, σ^6 -DMSO, 319 K): δ 172.5 (CO_2 CH₃), 154.0 (N(CO)O), 136.8 (Ar- C_q), 136.5 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 132.6 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 128.2 (Ar-C), 127.6 (Ar-C), 127.2 (Ar-C), 118.1 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 116.0 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 66.0 (CH₂Ph), 63.9 (3-C), 52.4 (NCH₂CH=CH₂), 51.0 (CO₂CH₃), 49.2 (2-C), 45.6 (NCH₂CH₂N), 43.2 (NCH₂CH₂N), 37.8 (C_qCH₂CH=CH₂). **IR** v_{max}(film)/cm⁻¹ 2950, 1734 (CO), 1706 (CO), 1458, 1431, 1283, 1225, 1124. **HRMS** (ESI): C₂₀H₂₇N₂O₄ [M+H]⁺; calculated 359.1965, found 359.1975.

Methyl 2-benzyl-2-[(prop-2-en-1-yl)amino]pent-4-enoate 15d



General procedure **J** was followed using amino ester **S2d** (400 mg, 1.82 mmol) and allyl bromide (0.8 mL, 9 mmol, 5 eq.). The reaction mixture was stirred for 2 days at rt. Purification by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, gave the *title compound* **15d** (297 mg, 1.15 mmol, 63%) as a pale yellow oil. ¹**H NMR** (500 MHz, CDCl₃, NH not observed): δ 7.18-7.07 (3H, m, Ar-H), 6.99 (2H, m, Ar-H), 5.87-5.67 (2H, m, NHCH₂C*H*=CH₂ and C_qCH₂C*H*=CH₂), 5.16-5.02 (4H, m, NHCH₂CH=C*H*₂ and C*H*₂), 3.52 (3H, s, CO₂CH₃), 3.12 (1H, dd, *J* 13.0, 5.8, NHC*H*_AH_BCH=CH₂), 3.05 (1H, dd,

C_qCH₂CH=C*H*₂), 3.52 (3H, s, CO₂CH₃), 3.12 (1H, dd, *J* 13.0, 5.8, NHC*H*_AH_BCH=CH₂), 3.05 (1H, dd, *J* 13.0, 6.1, NHCH_A*H*_BCH=CH₂), 2.88 (1H, d, *J* 13.6, C*H*_AH_BPh), 2.81 (1H, d, *J* 13.6, CH_A*H*_BPh), 2.41 (1H, dd, *J* 14.8, 6.5, C_qC*H*_AH_BCH=CH₂), 2.31 (1H, dd, *J* 14.8, 7.8, C_qCH_A*H*_BCH=CH₂). ¹³**C NMR** (125 MHz, CDCl₃, Ar- C_q not observed): δ 175.3 (CO_2 CH₃), 136.4 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 133.0 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 130.0 (Ar-C), 128.2 (Ar-C), 126.8 (Ar-C), 118.7 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 116.0 (NCH₂CH=CH₂ or C_qCH₂CH=CH₂), 66.0 (C_q), 51.7 (CO₂CH₃), 46.0 (NH*C*H₂CH=CH₂), 41.8 (*C*H₂Ph), 38.1 (C_qCH₂CH=CH₂). **IR** v_{max}(film)/cm⁻¹ 2949 (NH), 1731 (CO), 1495, 1454, 1119, 917, 701, 614. **HRMS** (ESI): C₁₆H₂₂NO₂ [M+H]⁺; calculated 260.1645, found 260.1647.

Methyl 1,2,3,5,8,8a-hexahydroindolizine-8a-carboxylate 16a


Method A: General procedure K was followed using amino ester 15a (266 mg, 1.27 mmol) with GII (27 mg, 32 μmol, 2.5 mol%) in PhMe. The residue was washed through a pad of silica with EtOAc–MeOH (9:1) to give the *title compound* 16a (191 mg, 1.05 mmol, 83%) as a red-brown oil. Method B: General procedure K was followed using amino

1.05 mmol, 83%) as a red-brown oil. **Method B:** General procedure **K** was followed using amino ester **15a** (1.89 g, 9.03 mmol) with two changes; the addition of p-TsOH was omitted and HGII (245 mg, 0.290 mmol, 3.20 mol%) was used as the catalyst. The residue was washed through a pad of silica with EtOAc–MeOH (9:1) to give the *title compound* (1.12 g, 6.18 mmol, 69% [100% conversion based on crude ¹H NMR study]) as a red-brown oil. **R**_f 0.28 (1:1 pentane–EtOAc). ¹**H NMR** (500 MHz, CDCl₃): δ 5.74-5.67 (2H, m, 6-H and 7-H), 3.67 (3H, s, CO₂CH₃), 3.55-3.48 (1H, m, 5-H_A), 3.40-3.33 (1H, m, 5-H_B), 3.18-2.98 (2H, m, 3-H), 2.86-2.71 (1H, m, 8-H_A), 2.23-2.08 (2H, m, 1-H_A and 8-H_B), 1.98-1.70 (3H, m, 1-H_B and 2-H). ¹³**C NMR** (125 MHz, CDCl₃): δ 175.6 (CO_2 CH₃), 125.9 (6-C or 7-C), 123.9 (6-C or 7-C), 65.5 (8a-C), 51.5 (CO_2 CH₃), 50.9 (3-C), 47.4 (5-C), 36.8 (1-C), 33.8 (8-C), 20.6 (2-C). **IR** V_{max} (film)/cm⁻¹ 3033, 2949, 2853, 1935 (C=C), 1731 (CO), 1447, 1192, 1175. **HRMS** (ESI): C_{10} H₁₆NO₂ [M+H]⁺; calculated 182.1181, found 182.1176.

Methyl 1-azabicyclo[4.2.0]oct-3-ene-6-carboxylate 16b

General procedure **K** was followed using amino ester **15b** (100 mg, 0.510 mmol) with GII (33 mg, 38 μ mol, 7.5 mol%) in PhMe. Flash chromatography eluting with a gradient of 0-10% MeOH in CH₂Cl₂, gave the *title compound* (49 mg, 0.29 mmol, 57%) as a red-brown oil. **R**_f 0.35 (10:1 CH₂Cl₂–MeOH). ¹**H NMR** (500 MHz, CDCl₃): δ 6.05-5.98 (1H, m, 3-H), 5.94-5.88 (1H, m, 4-H), 3.73 (3H, s, CO₂CH₃), 3.48-3.37 (2H, m, 2-H_A and 8-H_A), 3.18-3.11 (1H, m, 8-H_B), 2.95-2.88 (1H, m, 2-H_B), 2.69-2.60 (1H, m, 7-H_A), 2.43-2.39 (2H, m, 5-H), 2.03-1.96 (1H, m, 7-H_B). ¹³**C NMR** (125 MHz, CDCl₃): δ 175.8 (CO₂CH₃), 127.0 (4-C), 124.1 (3-C), 64.2 (6-C), 52.3 (CO₂CH₃), 49.0 (8-C), 47.4 (2-C), 30.5 (7-C), 28.5 (5-C). **IR** v_{max}(film)/cm⁻¹ 2952, 2928, 1734 (CO), 1437, 1267, 1225, 1202, 1156. **HRMS** (ESI): C₉H₁₄NO₂ [M+H]⁺; calculated 168.1019, found 168.1022.

2-Benzyl 9a-methyl 1H,2H,3H,4H,6H,9H,9aH-pyrido[1,2-a]piperazine-2,9a-dicarboxylate 16c



General procedure **K** was followed using amino ester **15c** (211 mg, 0.590 mmol) with GII (13 mg, 15 μmol, 2.5 mol%) in PhMe. Flash chromatography eluting with a gradient of 0-100% EtOAc in pentane (containing 1% Et₃N) gave the *title compound* **16c** (176 mg, 0.533 mmol, 90%) as a pale yellow oil. **R**_f 0.15 (3:2 petrol–EtOAc). ¹**H NMR** (500 MHz,

 σ^6 -DMSO, 319 K): δ 7.42-7.26 (5H, m, Cbz Ar-H), 5.69-5.58 (2H, m, 7-H and 8-H), 5.12-4.99 (2H, m, CH_2Ph), 4.25 (1H, dd, J13.1, 2.1, 1-H_A), 3.98-3.90 (1H, m, $NCH_AH_BCH_2N$), 3.47 (3H, s, CO_2CH_3), 3.38-3.30 (1H, m, $6-H_A$), 3.19-3.13 (1H, m, $6-H_B$), 3.10-2.99 (2H, m, $NCH_AH_BCH_2N$ and NCHAHBCH2N), 2.86 (1H, d, J 13.1, 1-HB), 2.65-2.55 (1H, m, NCHAHBCH2N), 2.44-2.33 (1H, m, 9-H_A), 2.11-2.02 (1H, m, 9-H_B). ¹³**C NMR** (125 MHz, d^6 -DMSO, 319 K): δ 172.3 (d^6 -DMSO, 153.8) (N(CO)O), 136.7 (Ar- C_q), 128.2 (Ar-C), 127.6 (Ar-C), 127.2 (Ar-C), 125.1 (7-C or 8-C), 121.2 (7-C or 8-C), 66.1 (CH₂Ph), 59.8 (9a-C), 51.6 (1-C), 50.9 (CO₂CH₃), 49.8 (6-C), 47.6 (NCH₂CH₂N), 43.4 (NCH₂CH₂N), 32.2 (9-C). **IR** v_{max}(film)/cm⁻¹ 3034, 2949, 1732 (CO), 1704 (CO), 1463, 1434, 1286, 1228. **HRMS** (ESI): C₁₈H₂₃N₂O₄ [M+H]⁺; calculated 331.1652, found 331.1652.

Methyl 2-benzyl-1,2,3,6-tetrahydropyridine-2-carboxylate 16d

General procedure K was followed using amino ester 15d (38 mg, 0.15 mmol) with CO₂Me HN²

GII (7.0 mg, 7.5 µmol, 5.0 mol%) in CH₂Cl₂. Flash chromatography eluting with pentane-EtOAc (4:1) gave the title compound 16d (24 mg, 0.10 mmol, 69%) as an 16d orange oil. \mathbf{R}_f 0.06 (4:1 petrol–EtOAc). ¹H NMR (500 MHz, CDCl₃): δ 7.31-7.22 (3H, m, Ar-H), 7.12-7.08 (2H, m, Ar-H), 5.74-5.69 (1H, m, 4-H), 5.69-5.64 (1H, m, 5-H), 3.62 (3H, s, CO₂CH₃), 3.54-3.48 (1H, m, $6-H_A$), 3.43-3.36 (1H, m, $6-H_B$), 3.04 (1H, d, J13.2, CH_AH_BPh), 2.91 (1H, d, J13.2, CH_AH_BPh), 2.68-2.61 (1H, m, 3-H_A), 2.31-2.24 (1H, m, 3-H_B). ¹³C NMR (125 MHz, CDCl₃): δ 175.3 (CO₂CH₃), 135.7 (Ar-C_q), 130.0 (Ar-C), 128.5 (Ar-C), 127.2 (Ar-C), 125.3 (5-C), 123.3 (4-C), 61.7 (2-C), 51.8 (CO₂CH₃), 46.5 (CH₂Ph), 42.7 (6-C), 33.3 (3-C). **IR** v_{max}(film)/cm⁻¹ 3030 (NH), 2949, 1730, (CO), 1454, 1435, 1200, 1110, 1084, 1041. **HRMS** (ESI): C₁₄H₁₈NO₂ [M+H]⁺; calculated 232.1332, found 232.1342.

1-tert-Butyl 2-methyl (2S)-pyrrolidine-1,2-dicarboxylate S1a


to a stirred solution of L-proline methyl ester hydrochloride (3.84 g, 23.2 mmol, 1.00 eq.) in CH₂Cl₂ (230 mL). The reaction mixture was stirred for 1 h, then concentrated in vacuo. The residue was triturated with Et₂O (3 x 50 mL) and filtered to remove the insoluble Et₃N·HCl. The resulting solution was dry-loaded onto silica. Flash chromatography eluting with pentane-EtOAc (4:1) gave the title compound \$1a (5.30 g, 23.1 mmol, 99%) as a colourless oil. \mathbf{R}_f 0.19 (4:1 petrol-EtOAc). $[\alpha]^{27}_{D}$ -61.4 (c. 0.83, MeOH) {lit. 13 -61.7 (c. 1.15, MeOH)}. ¹H NMR (300 MHz, CDCl₃, 2:3 mixture of rotamers): δ 4.34 (0.4H, dd, J 8.5, 3.1, 2-H), 4.23 (0.6H, dd, J 8.5, 4.1, 2-H), 3.73 (3H, s, CO₂CH₃), 3.62-3.33 (2H, m, 5-H), 2.33-2.09 (1H,

m, 3-H_A), 2.05-1.77 (3H, m, 3-H_B and 4-H), 1.47 (3.6H, s, C(CH₃)₃), 1.42 (5.4H, s, C(CH₃)₃). 13 C NMR

Boc₂O (5.20 g, 23.9 mmol, 1.03 eq.) and Et₃N (9.7 mL, 70 mmol, 2.9 eq.) were added

(75 MHz, CDCl₃, mixture of rotamers): δ 173.8 (major, CO₂CH₃), 173.5 (minor, CO₂CH₃), 154.5 (minor, N(CO)O), 153.8 (major, N(CO)O), 79.9 (major and minor, $C_q(CH_3)_3$), 59.2 (major, 2-C), 58.8 (minor, 2-C), 52.1 (minor, CO₂CH₃), 52.0 (major, CO₂CH₃), 46.6 (minor, 5-C), 46.4 (major, 5-C), 30.9 (major, 3-C), 30.0 (minor, 3-C), 28.5 (minor, C_q(CH₃)₃), 28.3 (major, C_q(CH₃)₃), 24.4 (minor, 4-C), 23.7 (major, 4-C). **IR** v_{max} (film)/cm⁻¹ 2977, 2882, 1747 (CO), 1694 (CO), 1393, 1201, 1121, 1088. **HRMS** (ESI): C₁₁H₁₉NNaO₄ [M+Na]⁺; calculated 252.1212, found 252.1206. Spectra consistent with the literature values.¹⁰

4-Benzyl 1-tert-butyl 2-methyl piperazine-1,2,4-tricarboxylate S1c



Benzyl chloroformate (3.5 mL, 24 mmol, 1.3 eq.) was added dropwise to a stirred solution of 1-*tert*-butyl 2-methyl piperazine-1,2-dicarboxylate* (4.59 g, 18.8 mmol, 1.00 eq.) and Et₃N (3.4 mL, 24 mmol, 1.3 eq.) in CH₂Cl₂ (50 mL) at 0 °C. The reaction mixture was warmed to rt and stirred for 15 h, then partitioned between H₂O (50 mL) and CH₂Cl₂ (50 mL). The organics were dried over MgSO₄, filtered, then concentrated *in vacuo*. Flash chromatography eluting with pentane–EtOAc (4:1) gave the *title compound* **S1c** (5.52 g, 14.6 mmol, 85%) as a straw-coloured

oil. **R**_f 0.11 (4:1 petrol–EtOAc). ¹**H NMR** (500 MHz, *σ*⁶-DMSO, 343 K): δ 7.40-7.29 (5H, m, Cbz Ar-H), 5.11 (1H, d, *J* 12.7, C*H*_AH_BPh), 5.07 (1H, d, *J* 12.7, CH_AH_BPh), 4.61 (1H, br. s, 2-H), 4.34 (1H, d, *J* 13.8, 3-H_A), 3.92-3.85 (1H, m, NC*H*_AH_BCH₂N), 3.74 (1H, dt, *J* 13.0, 3.4, NC*H*_AH_BCH₂N), 3.60 (3H, s, CO₂CH₃), 3.27 (1H, dd, *J* 13.8, 4.5, 3-H_B), 3.16-3.07 (1H, m, NCH_AH_BCH₂N), 3.04-2.03 (1H, m, NCH_AH_BCH₂N), 1.40 (9H, s, C(CH₃)₃). ¹³**C NMR** (125 MHz, *σ*⁶-DMSO, 373 K): δ 169.9 (*C*O₂CH₃), 154.0 (N(CO)O), 153.9 (N(CO)O), 136.3 (Ar-C_q), 127.8 (Ar-C), 127.2 (Ar-C), 126.8 (Ar-C), 79.5 (*C*_q(CH₃)₃), 66.0 (*C*H₂Ph), 53.7 (2-C), 51.3 (CO₂*C*H₃), 43.5 (3-C and N*C*H₂CH₂N), 42.3 (N*C*H₂CH₂N), 27.4 (C(*C*H₃)₃). **IR** v_{max}(film)/cm⁻¹ 2976, 1744 (CO), 1694, 1457, 1431, 1224, 1168, 1106. **HRMS** (ESI): C₁₉H₂₇N₂O₆ [M+H]⁺; calculated 379.1864, found 379.1866.

Methyl 2-(prop-2-en-1-yl)pyrrolidine-2-carboxylate S2a



General procedure **A** was followed using Boc-protected amino ester **1a** (6.7 g, 25 mmol). Purification by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, gave the *title compound* **S2a** (3.10 g, 18.3 mmol, 74%) as an orange oil. ¹**H NMR** (500 MHz, CDCl₃,

NH not observed): δ 5.78-5.69 (1H, m, C*H*=CH₂), 5.15-5.07 (2H, m, CH=C*H*₂), 3.74 (3H, s, CO₂CH₃), 3.14-3.02 (2H, m, 5-H), 2.61 (1H, ddt, *J* 13.7, 7.3, 1.1, C*H*_AH_BCH=CH₂), 2.45 (1H, ddt, *J* 13.7, 7.2,

51

^{*} Purchased from Fluorochem.

1.0, CH_AH_BCH=CH₂), 2.27-2.18 (1H, m, 3-H_A), 1.91-1.79 (2H, m, 3-H_B and 4-H_A), 1.79-1.68 (1H, m, 4-H_B). ¹³C NMR (125 MHz, CDCl₃): δ 176.3 (CO₂CH₃), 133.3 (CH=CH₂), 119.0 (CH=CH₂), 70.0 (2-C), 52.6 (CO_2CH_3) , 46.5 (5-C), 43.3 $(CH_2CH=CH_2)$, 35.2 (3-C), 24.7 (4-C). **IR** $v_{max}(film)/cm^{-1}$ 3352 (NH), 2953, 1732 (CO), 1435, 1217, 1200, 997, 918. **HRMS** (ESI): C₉H₁₆NO₂ [M+H]⁺; calculated 170.1181, found 170.1176.


Methyl 2-(prop-2-en-1-yl)azetidine-2-carboxylate S2b

[M]+; calculated 155.0945, found 155.0946.



General procedure A was followed using Boc-protected amino ester 1b (1.93 g, 7.53 mmol). Purification by SCX cartridge, eluting first with MeOH then sat. NH₃/MeOH, gave the title compound S2b (771 mg, 4.97 mmol, 66%) as an orange oil. 1H NMR (500 MHz, CDCl₃, NH not observed): δ 5.80-5.68 (1H, m, CH=CH₂), 5.14-5.07 (2H, m, CH=C H_2), 3.78 (3H, s, CO₂CH₃), 3.51 (1H, app. q, J7.9, 4-H_A), 3.37-3.31 (1H, m, 4-H_B), 2.63-2.51 (2H, m, CH₂CH=CH₂), 2.49-2.39 (2H, m, 3-H). ¹³C NMR (125 MHz, CDCl₃): δ 176.6 (CO₂CH₃), 132.2 $(CH=CH_2)$, 118.5 $(CH=CH_2)$, 67.4 (2-C), 52.3 (CO_2CH_3) , 43.8 $(CH_2CH=CH_2)$, 41.5 (4-C), 30.0 (3-C). IR v_{max}(film)/cm⁻¹ 3329, 2954, 2879, 1732 (CO), 1436, 1266, 1216, 1140. HRMS (EI): C₈H₁₃NO₂

1-Benzyl 3-methyl 3-(prop-2-en-1-yl)piperazine-1,3-dicarboxylate S2c



NH₃/MeOH, gave the title compound **S2c** (2.19 g, 6.88 mmol, 85%) as a colourless oil. \mathbf{R}_f 0.18 (3:2 pentane–EtOAc). ¹H NMR (500 MHz, σ 6-DMSO, 340 K): δ 7.41-7.28 (5H, m, Cbz Ar-H), 5.74-5.64 (1H, m, CH=CH₂), 5.13-5.03 (4H, m, CH_2Ph and $CH=CH_2$), 4.19 (1H, d, J 12.8, 3-H_A), 3.70 (1H, d, J 12.5, NCH_AH_BCH₂N), 3.58 (3H, s, CO₂CH₃), 3.00-2.92 (1H, m, NCH_AH_BCH₂N), 2.90 (1H, d, J 12.8, 3-H_B), 2.80-2.74 (1H, m, NCH_AH_BCH₂N), 2.73-2.66 (1H, m, NCH_AH_BCH₂N), 2.65 (1H, br. s, NH), 2.32 (1H, dd, J 13.8, 7.2, $CH_AH_BCH=CH_2$), 2.25 (1H, dd, J 13.8, 7.5, $CH_AH_BCH=CH_2$). ¹³**C NMR** (125 MHz, σ^6 -DMSO, 340 K): δ 173.2 (CO_2CH_3), 154.1 (N(CO)O), 136.7 (Ar-C_q), 131.7 ($CH=CH_2$), 128.0 (Ar-C), 127.4 (Ar-C), 127.0 (Ar-C), 118.4 (CH= CH_2), 65.9 (CH_2 Ph), 61.1 (2-C), 51.1 (CO_2CH_3), 49.0 (3-C), 43.2 (NCH₂CH₂), 41.0 (CH₂CH=CH₂ or NCH₂CH₂N), 40.8 (CH₂CH=CH₂ or NCH₂CH₂N). IR $v_{max}(film)/cm^{-1}$ 3564, 3339, 2951, 1731 (CO), 1704 (CO), 1434, 1358, 1229, 1122, 761. **HRMS** (ESI): C₁₇H₂₃N₂O₄ [MH⁺]; calculated 319.1652, found 319.1658.

General procedure A was followed using Boc-protected amino ester 1c (3.37 g,

8.05 mmol). Purification by SCX cartridge, eluting first with MeOH then sat.


Methyl 2-amino-2-benzylpent-4-enoate S2d



Benzaldehyde (1.2 mL, 12 mmol, 1.0 eq.) was added to a stirred suspension of L-phenylalanine methyl ester hydrochloride (2.5 g, 12 mmol, 1.0 eq.), Et_3N (1.6 mL, 12 mmol, 1.0 eq.) and 4 Å MS (500 mg) in THF (60 mL). The reaction mixture was stirred for 15 h, then filtered to remove the insoluble Et_3N +HCl and concentrated *in vacuo* to

S2d give the crude imine as a pale yellow oil. The residue was diluted in THF (60 mL) and LiHMDS (1.0 M in THF, 17.4 mL, 17.4 mmol, 1.50 eq.) was added dropwise at −78 °C. The reaction mixture was stirred for 15 min then allyl bromide (1.50 mL, 17.4 mmol, 1.50 eq.) was added dropwise. After 1 h the dry-ice bath was removed, the reaction mixture was warmed to rt and stirred for 15 h. Aqueous citric acid (15 wt%, 100 mL) was added and the reaction mixture was stirred for 1 h, then partitioned with Et₂O (100 mL). The aqueous layer was neutralised with solid NaHCO₃, then extracted with CH₂Cl₂ (3 × 50 mL). The combined organics were dried over Na₂SO₄ and concentrated in vacuo. The title compound **\$2d** (2.26 g, 10.3 mmol, 89%) was isolated as a yellow oil after flushing through a pad of silica with EtOAc-MeOH (9:1). Rf 0.14 (4:1 pentane-EtOAc). ¹**H NMR** (300 MHz, CDCl₃, NH₂ not observed): δ 7.24-7.10 (3H, m, Ar-H), 7.10-7.02 (2H, m, Ar-H), 5.70-5.54 (1H, m, CH=CH₂), 5.15-5.05 (2H, m, CH=CH₂), 3.62 (3H, s, CO₂CH₃), 3.11 (1H, d, J13.2, CH_AH_BPh), 2.71 (1H, d, J 13.2, CH_AH_BPh), 2.65 (1H, ddt, J 13.4, 6.4, 1.2, $CH_AH_BCH=CH_2$), 2.24 (1H, dd, J 13.4, 8.5, CH_AH_BCH=CH₂). ¹³C NMR (75 MHz, CDCl₃): δ 176.6 (CO₂CH₃), 136.2 (Ar-C₉), 132.6 (CH=CH₂), 129.9 (Ar-C), 128.5 (Ar-C), 127.1 (Ar-C), 119.9 (CH=CH₂), 62.0 (C_0), 52.1 (CO₂CH₃), 45.9 (CH₂Ph), 44.6 (CH₂CH=CH₂). **IR** v_{max}(film)/cm⁻¹ 3378, 2951, 1738 (CO), 1603, 1441, 1218, 1030, 922. **HRMS** C₁₃H₁₈NO₂ [M+H]⁺; calculated 220.1332, found 220.1340. Spectra consistent with the literature values.14

Methyl 2-benzyl-2-[(phenylcarbamoyl)amino]pent-4-enoate S3d




Phenyl isocyanate (180 μ L, 1.61 mmol, 1.05 eq.) was added to a stirred solution of amino ester **S2d** (337 mg, 1.54 mmol, 1.0 eq.) in PhMe (20 mL). Flash chromatography eluting with pentane–EtOAc (4:1) gave the *title compound* **S3d** (271 mg, 0.80 mmol, 52%) as a colourless solid. **R**_f 0.46 (4:1 pentane–EtOAc). ¹**H NMR** (500 MHz, CDCl₃): δ 7.32-7.18 (7H, m, Ar-H), 7.13-7.04 (3H, m, Ar-H), 6.23 (1H, br. s., NH), 5.75-5.61 (1H, m, C*H*=CH₂), 5.5 (1H, br. s., NH), 5.17-5.03 (2H, m, CH=C*H*₂), 3.84-3.75 (4H, m, includes 1H, m, C*H*_AH_BPh and at δ 3.78: 3H, s, CO₂CH₃), 3.42 (1H, dd, *J* 13.9, 7.1,

C*H*_AH_BCH=CH₂), 3.18 (1H, d, *J* 13.5, CH_A*H*_BPh), 2.65 (1H, dd, *J* 13.9, 7.6, CH_A*H*_BCH=CH₂).
¹³C NMR (125 MHz, CDCl₃): δ 173.8 (CO_2CH_3), 154.3 (CO), 138.6 (Ar-C_q), 136.6 (Ar-C_q), 132.7 (CH=CH₂), 130.0 (Ar-C), 129.4 (Ar-C), 128.4 (Ar-C), 127.0 (Ar-C), 124.0 (Ar-C), 121.1 (Ar-C), 119.1

 $(CH=CH_2)$, 65.8 (C_q) , 52.7 (CO_2CH_3) , 41.1 (CH_2Ph) , 40.3 $(CH_2CH=CH_2)$. **IR** $v_{max}(film)/cm^{-1}$ 3355, 3030, 1742 (CO), 1651 (CO), 1599, 1549, 1497, 1441. **HRMS** (ESI): $C_{20}H_{22}N_2NaO_3$ [M+Na]⁺; calculated 361.1523, found 361.1525.

Methyl 2-benzyl-2-(2-{[(tert-butoxy)carbonyl]amino}acetamido)pent-4-enoate S4d



Amino ester **S2d** (535 mg, 2.44 mmol, 1.0 eq.) was added to a stirred solution of N-Boc-glycine (855 mg, 4.88 mmol, 2.0 eq.), EDCI (936 mg, 4.88 mmol, 2.0 eq.) and Et₃N (0.85 mL, 6.10 mmol, 2.50 eq.) in CH₂Cl₂ (20 mL). The reaction mixture was stirred for 15 h. Additional N-Boc-glycine (855 mg, 4.88 mmol, 2.00 eq.) and EDCI (936 mg, 4.88 mmol, 2.00 eq.) were added and the reaction mixture was stirred for 3 h, then concentrated *in vacuo*. The residue was diluted with EtOAc (50 mL) and washed with H₂O (50 mL) and brine (50 mL). The organic layer was dried over

MgSO₄, filtered, then concentrated *in vacuo*. Flash chromatography eluting with pentane–EtOAc–Et₃N (80:20:1) gave the *title compound* **S4d** (790 mg, 2.09 mmol, 86%) as a colourless oil. \mathbf{R}_f 0.22 (4:1 petrol–EtOAc). ¹H NMR (500 MHz, CDCl₃): δ 7.28-7.20 (3H, m, Ar-H), 7.01 (2H, dd, J7.9, 1.4, Ar-H), 6.66 (1H, br. s, NH), 5.65-5.55 (1H, m, CH=CH₂), 5.13-5.06 (2H, m, CH=CH₂), 5.03 (1H, br. s, NH), 3.78 (3H, s, CO₂CH₃), 3.76-3.72 (3H, m, includes 2H, m, CH₂NHBoc and at δ 3.74: 1H, d, J 13.6, CH_AH_BPh), 3.38 (1H, dd, J 13.9, 7.1, CH_AH_BCH=CH₂), 3.14 (1H, d, J 13.6, CH_AH_BPh), 2.64 (1H, dd, J 13.9, 7.7, CH_AH_BCH=CH₂), 1.44 (9H, s, C(CH₃)₃). ¹³C NMR (125 MHz, CDCl₃): δ 172.9 (CO₂CH₃), 168.8 (NH(CO)CH₂), 155.9 (NH(CO)O), 136.1 (Ar-C_q), 132.1 (CH=CH₂), 129.7 (Ar-C), 128.4 (Ar-C), 127.1 (Ar-C), 119.3 (CH=CH₂), 80.1 (C_q(CH₃)₃), 66.0 (C_q), 52.7 (CO₂CH₃), 44.9 (CH₂NHBoc), 40.5 (CH₂CH=CH₂), 39.6 (CH₂Ph), 28.3 (C(CH₃)₃). IR V_{max}(film)/cm⁻¹ 3385, 2978, 1740 (CO), 1716 (CO), 1679, 1514, 1448, 1367. HRMS (ESI): C₂₀H₂₈N₂NaO₅ [M+Na]⁺; calculated 399.1890, found 399.1895.

7.4 Synthesis of scaffold derivatives

(3R*,4aR*)-3-(Azidomethyl)-1-oxo-octahydropyrrolo[1,2-c]pyrimidine-4a-carboxylic acid S5a



NaOH (14 mg, 0.35 mmol, 2.2 eq.) was added to a solution of urea **7a** (50 mg, 0.15 mmol, 1.0 eq.) in MeOH (0.3 mL) and the reaction mixture was stirred for 2 h by which point a colourless precipitate had formed. The reaction mixture was diluted with MeOH (10 mL), then Amberlite IR-120 (hydrogen form, 94 mg) was added at 0 °C.

The reaction mixture was stirred for 0.5 h, then filtered through Celite and concentrated *in vacuo*. The resulting residue was triturated with CHCl₃ to give the *title compound* **\$5a** (37 mg, 0.15 mmol, 99%) as a colourless solid. ¹**H NMR** (500 MHz, a^6 -DMSO, 343 K, CO₂H not observed): δ 6.13 (1H,


s, NH), 3.52-3.41 (2H, m, C $H_AH_BN_3$, 7-H_A), 3.40-3.29 (3H, m, CH_A H_BN_3 , 3-H, 7-H_B), 2.46-2.40 (1H, m, 4-H_A), 2.34-2.28 (1H, m, 5-H_A), 1.89-1.76 (2H, m, 5-H_B and 6-H_A), 1.75-1.63 (1H, m, 6-H_B), 1.46 (1H, app. t, J12.2, 4-H_B). ¹³**C NMR** (125 MHz, σ 6-DMSO): δ 175.1 (σ 0-H), 153.8 (1-C), 65.6 (4a-C), 53.5 (CH₂N₃), 48.5 (3-C), 44.9 (7-C), 37.4 (5-C), 33.6 (4-C), 21.1 (6-C). **IR** σ 1-1 (6-C) (1H), σ 1-1 (7-C) (1H), 153.8 (1-C), 65.6 (4a-C), 21.05 (N₃), 1685 (CO), 1530, 1453, 1308, 1233, 1078. **HRMS** (ESI): σ 2-H₁₄N₅O₃ [M+H]+; calculated 240.1091, found 240.1091. **X-Ray Crystallography**: CCDC 1008923 contains the supplementary crystallographic data for this compound. Crystals were grown by slow diffusion of Et₂O into the sample dissolved in the minimum amount of CHCl₃.

2-Benzyl 9a-methyl (8R*,9aS*)-8-(azidomethyl)-6-oxo-octahydro-1H-pyrimido[1,6 a]piperazine-2,9a-dicarboxylate S6c

NaOMe (25 wt% in MeOH, 18 μ L, 80 μ mol, 1.0 eq.) was added to a stirred solution of urea **7c** (37 mg, 80 μ mol, 1.0 eq.) in MeOH (0.8 mL). The reaction mixture was stirred at rt for 0.5 h, then concentrated *in vacuo*. The residue was redissolved in MeOH (10 mL) and Amberlite IR-120 (hydrogen form, 50 mg) was added. After stirring for 1 h the reaction

mixture was filtered and concentrated to give the *title compound* **S6c** (28 mg, 70 μmol, 88%) as a pale yellow oil. . **R**_f 0.16 (4:1 pentane–EtOAc). ¹**H NMR** (500 MHz, σ 6-DMSO, 319 K): δ 7.42-7.28 (5H, m, Cbz Ar-H), 6.68 (1H, s, NH), 5.11 (1H, d, J12.7, $CH_{A}H_{B}Ph$), 5.06 (1H, d, J12.7, $CH_{A}H_{B}Ph$), 4.50 (1H, d, J13.2, 1-H_A), 4.04 (1H, d, J12.1, NC $H_{A}H_{B}CH_{2}N$), 3.96 (1H, d, J13.1, NC $H_{A}H_{B}CH_{2}N$), 3.60 (3H, s, CO₂CH₃), 3.53-3.45 (1H, m, C $H_{A}H_{B}N_{3}$), 3.33-3.24 (2H, m, 8-H and CH_A $H_{B}N_{3}$), 3.01-2.84 (2H, m, 1-H_B and NCH_A $H_{B}CH_{2}N$), 2.83-2.73 (1H, m, NCH_A $H_{B}CH_{2}N$), 2.14 (1H, d, J12.7, 9-H_A), 1.78 (1H, app. t, J12.7, 9-H_B). ¹³**C NMR** (125 MHz, σ 6-DMSO, 319 K): δ 171.5 (CO₂CH₃), 154.9 (CO), 153.8 (CO), 136.5 (Ar-C_q), 128.2 (Ar-C), 127.7 (Ar-C), 127.3 (Ar-C), 66.3 (CH₂Ph), 61.3 (9a-C), 53.2 (CH₂N₃), 52.5 (CO₂CH₃), 50.2 (1-C), 46.6 (8-C), 42.8 (NCH₂CH₂N), 39.3 (NCH₂CH₂N), 32.2 (9-C). **IR** ν_{max} (film)/cm⁻¹ 2107 (N₃), 1738 (CO), 1704 (CO), 1664 (CO), 1432, 1284, 1234, 1122. **HRMS** (ESI): C₁₈H₂₃N₆O₅ [M+H]⁺; calculated 403.1724, found 403.1728. **X-Ray Crystallography**: CCDC 1008924 contains the supplementary crystallographic data for this compound. Crystals were grown by slow diffusion of Et₂O into the sample dissolved in the minimum amount of CHCl₃.


2-Ethyl 4a-methyl (3R*,4aR*)-1-oxo-3-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]-octahydropyrrolo[1,2-c]pyrimidine-2,4a-dicarboxylate S7



Phenyl acetylene (70 μ L, 0.62 mmol, 2.0 eq) was added to a stirred solution of azide **7a** (100 mg, 0.31 mmol, 1.0 eq.), Cu(OAc)₂ (11 mg, 60 μ mol, 20 mol%) and sodium ascorbate (24 mg, 0.12 mmol, 40 mol%) in degassed BuOH–H₂O (1:1, 2.0 mL). After 15 h the reaction mixture was extracted with

EtOAc (25 mL) and washed with brine (25 mL). The aqueous layer was extracted with EtOAc (2 × 10 mL). The combined organics were dried over MgSO₄, filtered and concentrated *in vacuo*. Flash chromatography on cyanosilica eluting with a gradient of 0-100% EtOAc in pentane, gave the *title compound* **S7** (117 mg, 0.27 mmol, 88%) as colourless oil. **R**_f 0.29 (EtOAc). ¹**H NMR** (500 MHz, CDCl₃): δ 7.88 (1H, s, triazole 5-H), 7.83 (2H, d, *J* 7.1, Ar-H), 7.41 (2H, t, *J* 7.6, Ar-H), 7.35-7.30 (1H, m, Ar-H), 4.69 (2H, app. d, *J* 4.4, CH₂Ar), 4.59-4.51 (1H, m, 3-H), 4.39-4.20 (2H, m, CH₂CH₃), 3.70 (3H, s, CO₂CH₃), 3.58-3.51 (1H, m, 7-Ha), 3.43-3.37 (1H, m, 7-Ha), 2.86 (1H, dd, *J* 13.6, 8.7, 4-Ha), 2.28-2.21 (1H, m, 5-Ha), 1.96-1.72 (4H, m, 4-Ha; 5-Ha and 6-H), 1.33 (3H, t, *J* 7.1, CH₂CH₃). ¹³**C NMR** (125 MHz, CDCl₃): δ 172.8 (CO₂CH₃), 154.5 (CO), 150.0 (CO), 148.5 (triazole 4-C), 130.5 (Ar-C_q), 129.0 (Ar-C), 128.4 (Ar-C), 126.1 (Ar-C), 121.2 (triazole 5-C), 65.6 (4a-C), 63.4 (CH₂CH₃), 53.2 (CH₂Ar), 53.2 (3-C), 53.1 (CO₂CH₃), 46.7 (7-C), 37.8 (5-C) 36.7 (4-C), 22.7 (6-C), 14.5 (CH₂CH₃). **IR** ν_{max} (film)/cm⁻¹ 2981, 1703 (CO), 1419, 1288, 1230, 1171, 835, 767. **HRMS** (ESI): C₂₁H₂₆N₅O₅ [M+H]⁺; calculated 428.1928, found 428.1930.

(3R*,4aR*)-1-oxo-3-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]-octahydropyrrolo[1,2-c]pyrimidine-4a-carboxylic acid S8



S8, R= 83:17 Me:H

NaOH (6.0 mg, 0.14 mmol, 2.0 eq.) was added to a stirred solution of urea $\bf S7$ (30 mg, 70 μ mol, 1.0 eq.) in MeOH (0.3 mL). The reaction mixture was stirred for 2 h, by which point a colourless solid had precipitated from the solution. The reaction mixture was diluted with MeOH (15 mL). Amberlite

IR-120 (hydrogen form, 100 mg) was added and the mixture was stirred for 0.5 h, then filtered and concentrated. The residue was triturated with CHCl₃ to give the *title compound* **S8** (20 mg, 83:17 mixture of ester:acid, 56 μ mol, 80%) as colourless solid. ¹H NMR (500 MHz, d^6 -DMSO, 318 K, ester peaks assigned): δ 8.52 (1H, s, triazole 5-H), 7.85-7.81 (2H, m, Ar-H), 7.46 (2H, t, *J* 7.7, Ar-H), 7.34 (1H, t, *J* 7.4, Ar-H), 6.49 (1H, s, NH), 4.56 (1H, dd, *J* 14.0, 4.5, C*H*_AH_BAr), 4.44 (1H, dd, *J* 14.0, 6.3, NCH_AH_BAr), 3.66 (3H, s, CO₂CH₃), 3.64-3.56 (1H, m, 3-H), 3.43-3.34 (1H, m, 7-H_A), 3.33-3.26 (1H,

^{*} Degassed by bubbling N₂ through the solvent.

m, 7-H_B), 2.40-2.33 (1H, m, 4-H_A), 2.30-2.23 (1H, m, 5-H_A), 1.85-1.75 (2H, m, 5-H_B and 6-H_A), 1.68-1.57 (1H, m, 6-H_B), 1.40 (1H, t, J 12.4, 4-H_B). Carboxylic acid characteristic peaks: δ 8.53 (1H, s, triazole 5-H), 6.40 (1H, s, NH). ¹³**C NMR** (125 MHz, σ 6-DMSO, 318 K, ester peaks assigned): δ 173.6 (CO_2CH_3), 153.3 (1-C), 146.3 (triazole 4-C), 130.5 (Ar-C_q), 128.7 (Ar-C), 127.7 (Ar-C), 125.0 (Ar-C), 122.1 (triazole 5-C), 65.8 (4a-C), 52.5 (CH_2Ar and CO_2CH_3), 48.5 (3-C), 44.9 (7-C), 37.3 (5-C), 33.8 (4-C), 20.8 (6-C). **IR** ν max(film)/cm⁻¹ 1737 (CO), 1649 (CO), 1488, 1473, 1221, 1170, 712, 693. **HRMS** (ESI): $C_{18}H_{22}N_5O_3$ [M+H]⁺; calculated 356.1717, found 356.1723.


Methyl (3R*,4aR*)-3-(azidomethyl)-1-oxo-octahydropyrrolo[1,2-c]pyrimidine-4a-carboxylate S9



NaOMe (25 wt% in MeOH, 82 μ L, 37 μ mol, 1.0 eq.) was added to a stirred solution of urea **7a** (120 mg, 0.370 mmol, 1.00 eq.) in MeOH (3.0 mL). The reaction mixture was stirred at rt for 1.5 h, then concentrated *in vacuo*. The residue was redissolved in MeOH (10 mL) and Amberlite IR-120 (hydrogen form, 240 mg) was added. After

stirring for 0.5 h the reaction mixture was filtered and concentrated to give the *title compound* (72 mg, 0.28 mmol, 76%) as a white solid which was carried on crude to the next step. ¹**H NMR** (300 MHz, CDCl₃, characteristic peaks): δ 5.47 (1H, s, NH), 3.74 (3H, s, CO₂CH₃), 3.67-3.53 (2H, m), 3.49 (1H, dd, *J* 11.5, 4.2), 3.44-3.34 (1H, m), 3.25 (1H, dd, *J* 11.5, 7.1), 2.57 (1H, dd, *J* 12.8, 2.4), 2.48-2.32 (1H, m), 2.01-1.69 (3H, m), 1.47-1.34 (1H, m).

Methyl (3R*,4aR*)-3-(azidomethyl)-2-[(4-fluorophenyl)methyl]-1-oxo-octahydropyrrolo[1,2-c]pyrimidine-4a-carboxylate S10



To a stirred solution of urea **S9** (72 mg, 0.28 mmol, 1.0 eq.) in DMF (2.0 mL) was added NaH (60% dispersion in oil, 13 mg, 0.31 mmol, 1.1 eq.). The reaction mixture was stirred for 10 min then 4-fluorobenzyl bromide (70 μ L, 0.56 mmol, 2.0 eq.) was added. The reaction mixture was stirred for 1 h then H₂O (0.1 mL) was added. The reaction mixture was diluted with Et₂O (10 mL) and washed with brine (10 mL). The


aqueous layer was extracted with Et₂O (10 mL), then the combined organic layers were dried over MgSO₄, filtered, and concentrated *in vacuo*. Flash chromatography on cyanosilica eluting with a gradient of 0-100% EtOAc in pentane, gave the *title compound* **S10** (53 mg, 0.15 mmol, 52%) as colourless oil. **R**_f 0.26 (EtOAc–petrol). ¹**H NMR** (500 MHz, CDCl₃): δ 7.21 (2H, app. dd, J 8.4, 5.5, Ar 2-H), 6.99 (2H, app. t, J 8.7, Ar 3-H), 5.32 (1H, d, J 15.9, C H_AH_BAr), 3.99 (1H, d, J 15.9, C H_AH_BAr), 3.74-3.63 (5H, m includes 2H, m, 7-H and at δ 3.66: 3H, s, C O₂C O₃, 3.48 (1H, dd, J 12.9, 5.2, C O₄O₈O₈, 3.31 (1H, dd, J 12.9, 2.8, C O₈O₈O₉, 3.23-3.17 (1H, m, 3-H), 2.60 (1H, dd, J 13.0, 5.0,


4-H_A), 2.42-2.36 (1H, m, 5-H_A), 1.98-1.75 (4H, m, 4-H_B; 5-H_B and 6-H). ¹³**C NMR** (125 MHz, CDCl₃): δ 174.3 (CO_2Me), 162.1 (d, J 245.6, Ar 4-C), 155.3 (1-C), 133.5 (Ar 1-C), 129.4 (d, J 7.8, Ar 2-C), 115.5 (d, J 21.3, Ar 3-C), 65.0 (4a-C), 52.8 (CO_2CH_3), 52.4 (CH_2N_3), 51.2 (3-C), 46.5 (7-C or CH_2Ar), 46.3 (7-C or CH_2Ar), 38.6 (5-C), 35.8 (4-C), 21.7 (6-C). **IR** v_{max} (film)/cm⁻¹ 2953, 2101 (N₃), 1733 (CO), 1635, 1509, 1450, 1350,1218. **HRMS** (ESI): $C_{17}H_{21}FN_5O_3$ [M+H]⁺; calculated 362.1623, found 362.1630.


8.0 References


- A. Jadhav, R. S. Ferreira, C. Klumpp, B. T. Mott, C. P. Austin, J. Inglese, C. J. Thomas, D. J. Maloney, B. K. Shoichet and A. Simeonov, *J. Med. Chem.*, 2010, **53**, 37–51.
- A. Nadin, C. Hattotuwagama and I. Churcher, *Angew. Chem. Int. Ed.*, 2012, **51**, 1114–1122.
- 3 J. J. Irwin, T. Sterling, M. M. Mysinger, E. S. Bolstad and R. G. Coleman, *J. Chem. Inf. Model.*, 2012, **52**, 1757–1768.
- 4 P. C. D. Hawkins, A. G. Skillman, G. L. Warren, B. A. Ellingson and M. T. Stahl, *J. Chem. Inf. Model.*, 2010, **50**, 572–584.
- 5 W. H. B. Sauer and M. K. Schwarz, *J. Chem. Inf. Comput. Sci.*, 2003, **43**, 987–1003.
- A. Schuffenhauer, P. Ertl, S. Roggo, S. Wetzel, M. A. Koch and H. Waldmann, *J. Chem. Inf. Model.*, 2006, **47**, 47–58.
- M. Pattarozzi, C. Zonta, Q. B. Broxterman, B. Kaptein, R. De Zorzi, L. Randaccio, P. Scrimin and G. Licini, *Org. Lett.*, 2007, **9**, 2365–2368.
- 8 M. Fujita, O. Kitagawa, T. Suzuki and T. Taguchi, *J. Org. Chem.*, 1997, **62**, 7330–7335.
- 9 V. Gracias, A. F. Gasiecki, J. D. Moore, I. Akritopoulou-Zanze and S. W. Djuric, *Tetrahedron Lett.*, 2006, **47**, 8977–8980.
- W. A. Loughlin, S. S. Schweiker, I. D. Jenkins and L. C. Henderson, *Tetrahedron*, 2013, **69**, 1576–1582.
- 11 P. N. Confalone, E. M. Huie, S. S. Ko and G. M. Cole, *J. Org. Chem.*, 1988, **53**, 482–487.
- 12 K. Dolbeare, G. F. Pontoriero, S. K. Gupta, R. K. Mishra and R. L. Johnson, *J. Med. Chem.*, 2003, **46**, 727–733.
- 13 P. Barraclough, P. Dieterich, C. A. Spray and D. W. Young, *Org. Biomol. Chem.*, 2006, **4**, 1483–1491.
- 14 P. Fang, M. R. Chaulagain and Z. D. Aron, *Org. Lett.*, 2012, **14**, 2130–2133.


9.0 NMR Spectra












































key nOe enhancement for $5d_{minor}$

